

SUGHRUE MION, PLLC

March 11, 2002

www.sughrue.com

BOX PCTCommissioner for Patents
Washington, D.C. 20231PCT/JP00/06162
-filed September 8, 2000

Re: Application of Fumie SATO, Tohru TANAMI, Hideo TANAKA, Naoya ONO, Makoto YAGI and Hitomi HIRANO
 PROSTAGLANDIN DERIVATIVES
 Assignee: **TAISHO PHARMACEUTICAL CO., LTD.**
 Our Ref: Q68885

Dear Sir:

The following documents and fees are submitted herewith in connection with the above application for the purpose of entering the National stage under 35 U.S.C. § 371 and in accordance with Chapter II of the Patent Cooperation Treaty:

- ☒ an executed Declaration and Power of Attorney.
- ☒ an English translation of the International Application.
- ☒ an executed Assignment and PTO 1595 form.
- ☒ International Search Report, Information Disclosure Statement and a Form PTO-1449.
- ☒ a Preliminary Amendment

It is assumed that copies of the International Application, the International Search Report, the International Preliminary Examination Report, and any Articles 19 and 34 amendments as required by § 371(c) will be supplied directly by the International Bureau, but if further copies are needed, the undersigned can easily provide them upon request.

The Government filing fee is calculated as follows:


Total claims	12	-	20	=		x	\$18.00	=	\$.00
Independent claims	1	-	3	=		x	\$84.00	=	\$.00
Base Fee									\$890.00
Multiple Dependent Claim Fee									\$280.00
TOTAL FILING FEE									\$1170.00
Recordation of Assignment									\$ 40.00
TOTAL FEE									\$1210.00

Checks for the statutory filing fee of \$1170.00 and Assignment recordation fee of \$40.00 are attached. You are also directed and authorized to charge or credit any difference or overpayment to Deposit Account No. 19-4880. The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.492 which may be required during the entire pendency of the application to Deposit Account No. 19-4880. A duplicate copy of this transmittal letter is attached.

Priority is claimed from:

<u>Country</u>	<u>Application No</u>	<u>Filing Date</u>
Japan	256727/1999	September 10, 1999
Japan	323804/1999	November 15, 1999
Japan	189121/2000	June 23, 2000

Respectfully submitted,


 Susan J. Mack
 Registration No. 30,951

SJM/amt

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Fumie SATO, et al.

Appln. No.: Not Yet Assigned

Confirmation No.: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Filed: March 11, 2002

Examiner: Not Yet Assigned

For: PROSTAGLANDIN DERIVATIVES

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination, please amend the above-identified application as follows:

IN THE SPECIFICATION:

Please delete the table on page 21 and replace it with the following new table:

Preliminary Amendment
Attorney Docket No. Q68885

Please delete the table on page 22 and replace it with the following new table:



167	β -Cl	(E)CH=CH	0	$S(CH_2)_2O$	(R)-2-methylhexyl	hydrogen	α	α
168	β -Cl	(E)CH=CH	0	$S(CH_2)_2O$	(S)-2-methylhexyl	hydrogen	α	α
169	β -Cl	(E)CH=CH	0	$S(CH_2)_2O$	(R)-1-methyl-3-hexynyl	hydrogen	α	α
170	β -Cl	(E)CH=CH	0	$S(CH_2)_2O$	(S)-1-methyl-3-hexynyl	hydrogen	α	α
171	β -Cl	(Z)CH=CH	0	$S(CH_2)_2S$	cyclohexyl	methyl	α	α
172	β -Cl	(E)CH=CH	0	$S(CH_2)_2S$	cyclopentyl	hydrogen	α	β
173	β -Cl	(E)CH=CH	0	$S(CH_2)_2S$	(R)-2-methylhexyl	hydrogen	α	α
174	β -Cl	(E)CH=CH	0	$S(CH_2)_2S$	(S)-2-methylhexyl	hydrogen	α	α
175	β -Cl	(E)CH=CH	0	$S(O)(CH_2)_2S(O)$	(R)-2-methylhexyl	hydrogen	α	α
176	β -Cl	(E)CH=CH	0	$S(O)(CH_2)_2S(O)$	(S)-2-methylhexyl	hydrogen	α	α
177	β -Cl	(E)CH=CH	0	$S(CH_2)_2S$	(R)-1-methyl-3-hexynyl	hydrogen	α	α
178	β -Cl	(E)CH=CH	0	$S(CH_2)_2S$	(S)-1-methyl-3-hexynyl	hydrogen	α	α
179	α -Cl	$C\equiv C$	0	$S(CH_2)_2O$	cyclohexyl	methyl	α	α
180	α -Cl	$C\equiv C$	0	$S(CH_2)_2O$	cyclohexyl	hydrogen	α	α
181	β -Cl	$C\equiv C$	0	$S(CH_2)_2O$	cyclopentyl	hydrogen	α	α
182	β -Cl	$C\equiv C$	0	$S(CH_2)_2O$	cycloheptyl	hydrogen	α	α
183	β -Cl	$C\equiv C$	0	$S(CH_2)_2O$	cyclopentylmethyl	hydrogen	α	α
184	β -Cl	$C\equiv C$	0	$S(CH_2)_2O$	cyclohexylmethyl	hydrogen	α	α
185	β -Cl	$C\equiv C$	0	$S(CH_2)_2O$	(R)-2-methylhexyl	hydrogen	α	α
186	β -Cl	$C\equiv C$	0	$S(CH_2)_2O$	(S)-2-methylhexyl	hydrogen	α	α
187	β -Cl	$C\equiv C$	0	$S(CH_2)_2O$	(R)-2,6-dimethyl-5-heptenyl	hydrogen	α	α
188	β -Cl	$C\equiv C$	0	$S(CH_2)_2O$	(S)-2,6-dimethyl-5-heptenyl	hydrogen	α	α
189	β -Cl	$C\equiv C$	0	$S(CH_2)_2S(O)$	cyclohexyl	methyl	α	α
190	β -Cl	$C\equiv C$	0	$S(CH_2)_2S(O)$	cyclohexyl	hydrogen	α	α

14 13 12 11 10 9 8 7 6 5 4 3 2 1

191	β -Cl	$C\equiv C$	0	$S(O)_2(CH_2)_2S(O)_2$	cyclohexyl	methyl	α	α
192	β -Cl	$C\equiv C$	0	$S(O)_2(CH_2)_2S(O)_2$	cyclohexyl	hydrogen	α	α
193	α -Cl	$C\equiv C$	0	$S(CH_2)_2S$	cyclohexyl	methyl	α	α
194	α -Cl	$C\equiv C$	0	$S(CH_2)_2S$	cyclohexyl	hydrogen	α	α
195	β -Cl	$C\equiv C$	0	$S(CH_2)_2S$	cyclopentyl	hydrogen	α	α
196	β -Cl	$C\equiv C$	0	$S(CH_2)_2S$	cycloheptyl	hydrogen	α	α
197	β -Cl	$C\equiv C$	0	$S(CH_2)_2S$	cyclopentylmethyl	hydrogen	α	α
198	β -Cl	$C\equiv C$	0	$S(CH_2)_2S$	cyclohexylmethyl	hydrogen	α	α
199	β -Cl	$C\equiv C$	0	$S(CH_2)_2S$	(R)-2-methylhexyl	hydrogen	α	α
200	β -Cl	$C\equiv C$	0	$S(CH_2)_2S$	(S)-2-methylhexyl	hydrogen	α	α
201	β -Cl	$C\equiv C$	0	$S(CH_2)_2S$	(R)-2,6-dimethyl-5-heptenyl	hydrogen	α	α
202	β -Cl	$C\equiv C$	0	$S(CH_2)_2S$	(S)-2,6-dimethyl-5-heptenyl	hydrogen	α	α
203	α -Cl	$C\equiv C$	0	$S(CH_2)_2S$	(R)-2-methylhexyl	hydrogen	α	α
204	α -Cl	$C\equiv C$	0	$S(CH_2)_2S$	(S)-2-methylhexyl	hydrogen	β	β
205	F	$C\equiv C$	0	$S(CH_2)_2S$	(R)-2,6-dimethyl-5-heptenyl	hydrogen	α	α
206	F	$C\equiv C$	0	$S(CH_2)_2S$	(S)-2,6-dimethyl-5-heptenyl	hydrogen	α	α

199 200 201 202 203 204 205 206

Preliminary Amendment
Attorney Docket No. Q68885

Pages 25, please delete the partial paragraph at the top of page 25 and replace it with the following new paragraph:

2930,2850,1735,1640,1470,1380,1255,830,770

Page 34, please delete the second full paragraph and replace it with the following new paragraph:

4-Thia-16,17,18,19,20-pentanol-15-cyclohexyl-13,14-didehydro-PGF₁β ethyl ester 11,15-bis(tert-butyl)dimethylsilyl ether)

¹H-NMR(CDCl₃,200MHz)δppm;

0.07(s,3H),0.08(s,6H),0.11(s,3H),0.82-1.98(m,19H), 0.88(s,9H),0.90(s,9H),1.27(t,J=7.1Hz,3H),2.17-2.86(m,5H), 2.60(t, J=6.8Hz,2H),3.93-4.28(m,2H),4.08(dd,J=6.4,1.8Hz,1H), 4.16(q,J=7.1Hz,2H)

IR(neat):

3458,2929,2854,1739,1639,1472,1371,1342,1250,1065,898, 837,777,670

Page 37, please delete the partial paragraph at the top of page 37 and replace it with the following new paragraph:

¹H-NMR(CDCl₃,200MHz)δppm

0.00(s,3H),0.01(s,3H),0.04(s,3H),0.07(s,3H),0.73-

1.89(m,11H),0.88(s,9H),0.90(s,9H),2.33(dd,J=17.9,6.3Hz,1H),2.65(dd,J=17.9,6.3Hz,1H),3.27-

3.91(m,2H),4.07-

4.20(m,1H),5.25(dd,J=2.5,1.0Hz,1H),5.47(ddd,J=15.9,7.2,0.8Hz,1H),5.61(dd,J=15.5,5.1Hz,1H),6.12(dd,J=2.9,1.0Hz,1H)

IR(neat) cm⁻¹ ;

2954,2929,2856,1734,1642,1472,1451,1388,1361,1253,1113,

1071,1006,973,943,923,900,837,776,690

Page 44, please delete the first full paragraph and replace it with the following new paragraph:

(1) Following the substantially same manner as in Example 1(2) using methyl 5-mercapto-3-oxapentanoate in place of methyl 5-mercaptopentanoate in Example 1(2), thereby 3-oxa-6-thia-16,17,18,19,20-pentano-15-cyclohexyl-13,14-didehydro-PGE₁ methyl ester 11,15-bis(tert-butyldimethylsilyl ether) was obtained.

¹H-NMR(CDCl₃,200MHz)δppm;

0.08(s,3H),0.09(s,3H),0.10(s,3H),0.13(s,3H),0.82-

1.92(m,11H),0.89(s,9H),0.90(s,9H),2.22(dd,J=18.0,6.4Hz, 1H),2.40-2.82(m,2H),2.77(t,J=6.7Hz,2H),

2.92(d, J=5.9Hz,2H), 3.09-3.20(m,1H),3.71(t,J=6.7Hz,2H), 3.76(s,3H),

4.08(dd,J=6.2,1.8Hz,1H),4.13(s,2H),4.28-4.42(m,1H)

IR(neat) cm⁻¹;

2930,2855,2236,1752,1472,1464,1451,1390,1362,1252,1208,

1138,1066,1006,940,898,837,779,670,579

Page 49, please delete the first full paragraph and replace it with the following new paragraph:

(4) Following the substantially same manner as in Example 1(5) using the compound obtained in the above (3), thereby the title compound was obtained.

¹H-NMR(CDCl₃,200MHz)δppm;

0.98-2.02(m,13H),2.22-2.47(m,3H), 2.62(ddd,J=10.1,6.4,1.8Hz,1H),2.75-2.99(m,6H),

3.28(s,2H),3.76(s,3H),4.10(m,2H),4.06-4.27(m,2H),4.32-4.47(m,1H)

IR(neat) cm⁻¹;

3400,2925,2852,2236,1734,1730,1436,1284,1203,1142,1083, 1008,893,833,773,692,578


2002 MAR 11 10 30 AM

Preliminary Amendment
Attorney Docket No. Q68885

REMARKS

Entry and consideration of this Amendment is respectfully requested.

Respectfully submitted,


Susan J. Mack
Registration No. 30,951

SUGHRUE MION, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3213
Telephone: (202) 293-7060
Facsimile: (202) 293-7860
SJM/amt
Date: March 11, 2002

Preliminary Amendment
Attorney Docket No. Q68885

APPENDIX

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

The specification is changed as follows:

Table on page 21:

167	β -Cl	(E) CH=CH	0	$S(CH_2)_2O$	(R)-2-methylhexyl	hydrogen	α	α
168	β -Cl	(E) CH=CH	0	$S(CH_2)_2O$	(S)-2-methylhexyl	hydrogen	α	α
169	β -Cl	(E) CH=CH	0	$S(CH_2)_2O$	(R)-1-methyl-3-hexynyl	hydrogen	α	α
170	β -Cl	(E) CH=CH	0	$S(CH_2)_2O$	(S)-1-methyl-3-hexynyl	hydrogen	α	α
171	β -Cl	(Z) CH=CH	0	$S(CH_2)_2S$	cyclohexyl	methyl	α	α
172	β -Cl	(E) CH=CH	0	$S(CH_2)_2S$	cyclopentyl	hydrogen	α	β
173	β -Cl	(E) CH=CH	0	$S(CH_2)_2S$	(R)-2-methylhexyl	hydrogen	α	α
174	β -Cl	(E) CH=CH	0	$S(CH_2)_2S$	(S)-2-methylhexyl	hydrogen	α	α
175	β -Cl	(E) CH=CH	0	$S(O)(CH_2)_2S(O)$	(R)-2-methylhexyl	hydrogen	α	α
176	β -Cl	(E) CH=CH	0	$S(O)(CH_2)_2S(O)$	(S)-2-methylhexyl	hydrogen	α	α
177	β -Cl	(E) CH=CH	0	$S(CH_2)_2S$	(R)-1-methyl-3-hexynyl	hydrogen	α	α
178	β -Cl	(E) CH=CH	0	$S(CH_2)_2S$	(S)-1-methyl-3-hexynyl	hydrogen	α	α
179	α -Cl	CH \equiv CH	0	$S(CH_2)_2O$	cyclohexyl	methyl	α	α
180	α -Cl	CH \equiv CH	0	$S(CH_2)_2O$	cyclohexyl	hydrogen	α	α
181	β -Cl	CH \equiv CH	0	$S(CH_2)_2O$	cyclopentyl	hydrogen	α	α
182	β -Cl	CH \equiv CH	0	$S(CH_2)_2O$	cycloheptyl	hydrogen	α	α
183	β -Cl	CH \equiv CH	0	$S(CH_2)_2O$	cyclopentylmethyl	hydrogen	α	α
184	β -Cl	CH \equiv CH	0	$S(CH_2)_2O$	cyclohexylmethyl	hydrogen	α	α
185	β -Cl	CH \equiv CH	0	$S(CH_2)_2O$	(R)-2-methylhexyl	hydrogen	α	α
186	β -Cl	CH \equiv CH	0	$S(CH_2)_2O$	(S)-2-methylhexyl	hydrogen	α	α
187	β -Cl	CH \equiv CH	0	$S(CH_2)_2O$	(R)-2,6-dimethyl-5-heptenyl	hydrogen	α	α
188	β -Cl	CH \equiv CH	0	$S(CH_2)_2O$	(S)-2,6-dimethyl-5-heptenyl	hydrogen	α	α
189	β -Cl	CH \equiv CH	0	$S(CH_2)_2S(O)$	cyclohexyl	methyl	α	α
190	β -Cl	CH \equiv CH	0	$S(CH_2)_2S(O)$	cyclohexyl	hydrogen	α	α

Preliminary Amendment
Attorney Docket No. Q68885

Table on page 22:

Preliminary Amendment
Attorney Docket No. Q68885

Pages 25, partial paragraph at the top of page 25:

2930,2850,1375,1735,1640,1470,1380,1255,830,770

Page 34, second full paragraph:

4-Thia-16,17,18,19,20-pentanor-15-cyclohexyl-13,14-didehydro-PGF₁β ethyl ester 11,15-bis(tert-butyl dimethylsilyl ether)

¹H-NMR(CDCl₃,200MHz)δppm;

0.07(s,3H),0.08(s,6H),0.11(s,3H),0.82-1.98(m,19H), 0.88(s,9H),0.90(s,9H),1.27(t,J=7.1Hz,3H),2.17-2.86(m,5H), 2.60(t,J=6.8Hz,2H),3.93-4.28(m,2H),4.08(dd,J=6.4,1.8Hz,1H), 4.16(q,J=7.1Hz,2H)

IR(neat):

3458,2929,2854,1739,1639,1472,1371,1342,1250,1065,898, 837,777,670

Page 37, partial paragraph at the top paragraph:

¹H-NMR(CDCl₃,200MHz)δppm;

0.00(s,3H),0.01(s,3H),0.04(s,3H),0.07(s,3H),0.73-

1.89(m,11H),0.88(s,9H),0.90(s,9H),2.33(dd,J=17.9,6.3Hz,1H),2.65(dd,J=17.9,6.3Hz,1H),3.27-3.91(m,2H),4.07-

4.20(m,1H),5.25(dd,J=2.5,1.0Hz,1H),5.47(ddd,J=15.9,7.2,0.8Hz,1H),5.61(dd,J=15.5,5.1Hz,1H),6.12(dd,J=2.9,1.0Hz,1H)

IR(neat) cm⁻¹;

2954,2929,2856,1734,1642,1472,1451,1388,1361,1253,1113,
1071,1006,973,943,923,900,837,776,690

Page 44, first full paragraph:

(1) Following the substantially same manner as in Example 1(2) using methyl 5-mercapto-3-oxapentanoate in place of methyl 5-mercaptopentanoate in Example 1(2), thereby 3-oxa-6-thia-16,17,18,19,20-pentanor-15-cyclohexyl-13,14-didehydro-PGE₁ methyl ester 11,15-bis(tert-butyl dimethylsilyl ether) was obtained.

Preliminary Amendment
Attorney Docket No. Q68885

$^1\text{H-NMR}(\text{CDCl}_3, 200\text{MHz})\delta\text{ppm};$

0.08(s,3H),0.09(s,3H),0.10(s,3H),0.13(s,3H),0.82-
1.92(m,11H),0.89(s,9H),0.90(s,9H),2.22(dd,J=18.0,6.4Hz, 1H),2.40-2.82(m,2H),2.77(t,J=6.7Hz,2H),
2.92(d,J=5.9Hz,2H), 3.09-3.20(m,1H),3.71(t,J=6.7Hz,2H), 3.76(s,3H),
4.08(dd,J=6.2,1.8Hz,1H),4.13(s,2H),4.28-4.42(m,1H)

IR(neat) $\text{cm}^{-1};$

2930,2855,2236,1752,1472,1464,1451,1390,1362,1252,1208,
1138,1066,1006,940,898,837,779,670,579

Page 49, first full paragraph:

(54) Following the substantially same manner as in Example 1(5) using the compound obtained in the above (43), thereby the title compound was obtained.

$^1\text{H-NMR}(\text{CDCl}_3, 200\text{MHz})\delta\text{ppm};$

0.98-2.02(m,13H),2.22-2.47(m,3H), 2.62(ddd,J=10.1,6.4,1.8Hz,1H),2.75-2.99(m,6H),
3.28(s,2H),3.76(s,3H),4.10(m,2H),4.06-4.27(m,2H),4.32-4.47(m,1H)

IR(neat) $\text{cm}^{-1};$

3400,2925,2852,2236,1734,1730,1436,1284,1203,1142,1083, 1008,893,833,773,692,578

/

SPECIFICATION

PROSTAGLANDIN DERIVATIVES

TECHNICAL FIELD

The present invention relates to novel prostaglandin
5 derivatives, pharmaceutically acceptable salts thereof and
hydrates thereof.

BACKGROUND ART

Since prostaglandin (PG) exhibits various important
physiological actions in a trace amount, the biological
10 activities of a great number of natural PGs and synthesized
PG derivatives have been investigated with the intention
of a practical use as medicines and have been reported in
many literatures and patents. Among them, Japanese Patent
Kohyo Hei 2-502009 discloses a group of PG derivatives
15 substituted with a halogen atom at the 9-position.
Furthermore, PG derivatives having a PGD₂-like agonistic
activity are reported by K-H Thierauch et al., in Drug of
the Future, vol. 17, page 809 (1992).

In addition, PGs have been not only reported on their
20 various central nervous actions and but also clarified as
to the intracerebral content, biosynthesis, metabolic
pathway, their intracerebral localization and changes with
growth or aging, and there has been taken an interest in
the relation between sleep and wake by PGs. Among them,
25 PGD₂ has been known as an intracerebral humoral factor
which controls the occurrence or maintenance of sleep, and
it was made clear that the sleep induced by PGD₂ in monkeys
is undistinguished from their spontaneous natural sleep in

brain wave or behavior (Proc. Natl. Acad. Sci. USA, vol. 85, pp. 4082-4086 (1988)), therefore this compound was expected as a new compound having a sleep-inducing action.


However, PGD₂ derivatives including PGD₂ are
 5 presently unpractical due to the problems concerning their intracerebral transition and stability. Furthermore, there has not been specifically reported about sleep-inducing action of PG derivatives other than PGD₂ derivatives.

An object of the present invention is to provide
 10 novel PG derivatives having a PGD₂-like agonistic activity and a sleep-inducing action.

DISCLOSURE OF THE INVENTION

As a result of the continued extensive studies, the present inventors have found that novel prostaglandin
 15 derivatives represented by the following Formula (I) achieve the above-objects, and thereby the present invention has been accomplished.

That is, the present invention is directed to a prostaglandin derivative represented by Formula (I):



20 [wherein X is a halogen atom in the α - or β -position, Y is an ethylene group, a vinylene group or an ethynylene group, A is a group represented by the formula: $O(CH_2)_n$,

$S(O)_p(CH_2)_n,$

$O(CH_2)_qO(CH_2)_r,$

$O(CH_2)_qS(O)_p(CH_2)_r,$

$S(O)_p(CH_2)_qS(O)_p(CH_2)_r$ or

5 $S(O)_p(CH_2)_qO(CH_2)_r$

(wherein n is an integer of 1 to 5, p is 0, 1 or 2, q is an integer of 1 to 3, and r is 0 or 1),

R^1 is a C_{3-10} cycloalkyl group, a C_{1-4} alkyl- C_{3-10}

cycloalkyl group, a C_{3-10} cycloalkyl- C_{1-4} alkyl group, a

10 C_{5-10} alkyl group, a C_{5-10} alkenyl group, a C_{5-10} alkynyl group or a bridged cyclic hydrocarbon group,

R^2 is a hydrogen atom, a C_{1-10} alkyl group or a C_{3-10} cycloalkyl group, and

m is 0, 1 or 2], a pharmaceutically acceptable salt thereof
15 or a hydrate thereof.

Furthermore, the present invention is directed to a pharmaceutical preparation which comprises as an effective ingredient the compound represented by formula (I), the pharmaceutically acceptable salt thereof or the hydrate
20 thereof.

In the present invention, the vinylene group refers to a cis- or a trans-vinylene group. The halogen atom refers to a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.

25 The C_{3-10} cycloalkyl group means a cycloalkyl group having 3 to 10 carbon atoms, examples of which are a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group and a cycloheptyl group.

The C₁₋₄ alkyl-C₃₋₁₀ cycloalkyl group means a cycloalkyl group having 3 to 10 carbon atoms substituted with a straight or branched alkyl group having 1 to 4 carbon atoms, examples of which are a methylcyclopropyl group, a methylcyclohexyl group and an ethylcyclohexyl group.

The C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl group means a straight or branched alkyl group having 1 to 4 carbon atoms substituted with a cycloalkyl group having 3 to 10 carbon atoms, examples of which are a cyclopropylmethyl group, a cyclobutylmethyl group, a cyclopentylmethyl group, a cyclopentylethyl group, a cyclohexylmethyl group, a cyclohexylethyl group and a cycloheptylmethyl group.

The C₅₋₁₀ alkyl group means a straight or branched alkyl group having 5 to 10 carbon atoms, and examples of which are a pentyl group, a hexyl group, a heptyl group, an octyl group, a 1-methylpentyl group, a 2-methylpentyl group, a 1-methylhexyl group, a 2-methylhexyl group, a 2,4-dimethylpentyl group, a 2-ethylpentyl group, a 2-methylheptyl group, a 2-ethylhexyl group, a 2-propylpentyl group, a 2-propylhexyl group and a 2,6-dimethylheptyl group.

The C₅₋₁₀ alkenyl group means a straight or branched alkenyl group having 5 to 10 carbon atoms, examples of which are a 3-pentenyl group, a 4-hexenyl group, a 5-heptenyl group, a 4-methyl-3-pentenyl group, a 2,4-dimethylpentenyl group, a 6-methyl-5-heptenyl group and a 2,6-dimethyl-5-heptenyl group.

The C₅₋₁₀ alkynyl group means a straight or branched

alkynyl group having 5 to 10 carbon atoms, examples of which are a 3-pentynyl group, a 3-hexynyl group, a 4-hexynyl group, a 1-methylpent-3-ynyl group, a 2-methylpent-3-ynyl group, a 1-methylhex-3-ynyl group and a 2-methylhex-3-ynyl group.

Examples of the bridged cyclic hydrocarbon group are a bornyl group, a norbornyl group, an adamantyl group, a pinanyl group, a thujyl group, a caryl group and a camphanyl group.

The C₁₋₁₀ alkyl group means a straight or branched alkyl group having 1 to 10 carbon atoms, examples of which are a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a tert-butyl group, a pentyl group, an isopentyl group, a 2-ethylpropyl group, a hexyl group, an isohexyl group, a 1-ethylbutyl group, a heptyl group, an isoheptyl group, an octyl group, a nonyl group and a decyl group.


Examples of the pharmaceutically acceptable salt are salts with alkali metals (e.g., sodium or potassium), alkali earth metals (e.g., calcium or magnesium), ammonia, methylamine, dimethylamine, cyclopentylamine, benzylamine, piperidine, monoethanolamine, diethanolamine, monomethylmonoethanolamine, tromethamine, lysine, a tetraalkyl ammonium and tris(hydroxymethyl)aminomethane.

Preferable compounds of the present invention are those of Formula (I) wherein R¹ is a C₃₋₁₀ cycloalkyl group, a C₁₋₄ alkyl-C₃₋₁₀ cycloalkyl group, a C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl group, a branched C₅₋₁₀ alkyl group, a branched

C₅₋₁₀ alkenyl group, a branched C₅₋₁₀ alkynyl group or a bridged cyclic hydrocarbon group. Further preferable compounds of the present invention are those of Formula (I) wherein X is a chlorine or bromine atom in the α- or β-
 5 position, R¹ is a C₃₋₁₀ cycloalkyl group, a C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl group or a branched C₅₋₁₀ alkenyl group, and R² is a hydrogen atom or a C₁₋₁₀ alkyl group.

Furthermore, Y is preferably a vinylene group or an ethynylene group, and more preferably an ethynylene group.
 10 A is preferably a group represented by the formula:
 $S(O)_p(CH_2)_n$, $S(O)_p(CH_2)_qS(O)_p(CH_2)_r$ or $S(O)_p(CH_2)_qO(CH_2)_r$,
 and more preferably a group represented by the formula:
 $S(CH_2)_n$, $S(CH_2)_qS(CH_2)_r$ or $S(CH_2)_qO(CH_2)_r$.

The compounds of Formula (I) can be prepared, for
 15 example, by the methods summarized by the following reaction scheme.



azobiscyclohexanecarbonitrile, benzoyl peroxide or triethyl borane), if necessary, further using 1 to 5 equivalents of a radical reductant (e.g., tributyltin hydride, triphenyltin hydride, dibutyltin hydride or diphenyltin hydride) in an inert solvent (e.g., benzene, toluene, xylene, n-hexane, n-pentane or acetone) at -78 to 100°C to give a compound of Formula (VII). Depending on the situation, the compound of Formula (VII) can be also obtained by a reaction using 0.05 to 2 equivalents of a base (e.g. an organic amine such as triethylamine, diisopropylamine, pyridine or dimethylaniline, or a base resin such as polyvinylpyrrolidone, diisopropylaminomethyl - polystyrene or (piperidinomethyl)polystyrene) and, if necessary, using 0.01 to 0.5 equivalent of a bivalent palladium complex or complex salt (e.g. dichlorobis(acetonitrile)palladium (II), dichlorobis(benzonitrile)palladium (II) or palladium chloride) in an inert solvent (e.g., benzene, toluene, xylene, n-hexane, n-pentane or acetone) at -78 to 100°C.

(3) The compound of Formula (VII) is reacted with 0.5 to 5 equivalents of a reductant (e.g., potassium borohydride, sodium borohydride, lithium tricyanoborohydride, lithium tri-sec-butyl borohydride or diisobutylaluminum hydride - BHT (2,6-di-tert-butyl-p-cresol) in an organic solvent (e.g., tetrahydrofuran, diethyl ether, ethyl alcohol or methyl alcohol) at -78 to 40°C to give compounds of Formulae (VIII) and (VIII'). These compounds of Formulae (VIII) and (VIII') can be

XX

purified by a conventional separation method such as column chromatography.

(4) The compound of Formula (VIII) or (VIII') is mesylated or tosylated, for example, with 1 to 6 equivalents of methanesulfonyl chloride or p-toluenesulfonyl chloride in a proper solvent such as pyridine or toluene (if necessary, in the presence of 0.8 to 6 equivalents of a base such as triethylamine or 4-dimethylaminopyridine) at -20 to 40°C, followed by chlorination with 1 to 16 equivalents of tetra-n-butylammonium chloride to give a compound of Formula (IX) or (IX') wherein X is a chlorine atom, respectively. Herein, bromination or fluorination can be also carried out in an ordinary manner. For example, bromination can be carried out by a reaction using 1 to 10 equivalents of carbon tetrabromide in the presence of 1 to 10 equivalents of triphenylphosphine and 1 to 10 equivalents of pyridine in acetonitrile. Fluorination can be carried out, for example, by a reaction with 5 to 20 equivalents of diethylaminosulfur trifluoride (DAST) in methylene chloride.

(5) The tert-butyldimethylsilyl group of the compound of Formula (IX) or (IX') is removed by using hydrofluoric acid, pyridinium poly(hydrogenfluoride) or hydrochloric acid in a solvent (e.g., methanol, ethanol, acetonitrile, a mixture thereof or a mixture of these solvent(s) and water) under conventional conditions to give a PG derivative of Formula (Ia) or (Ia') of the present invention.

(6) The compound of Formula (Ia) or (Ia') is hydrolyzed using 1 to 6 equivalents of a base in a

conventional solvent for hydrolysis to give a PG derivative of Formula (Ib) or (Ib') of the present invention.

Examples of the base to be used are lithium hydroxide and potassium carbonate, and examples of the solvent to be used
5 are acetonitrile, acetone, methanol, ethanol, water and a mixture thereof.

Furthermore, the compound of Formula (Ia) is hydrolyzed by a reaction with an enzyme in a buffer solution such as phosphate buffer or tris-hydrochloride buffer, if necessary, by using an organic solvent (e.g. a water-miscible solvent such as acetone, methanol or ethanol) to give a PG derivative (Ib) of the present invention. Examples of the enzyme to be used are enzymes produced by microorganisms (e.g. enzymes produced by microorganisms belonging to *Candida* sp. or *Pseudomonas* sp.) and enzymes prepared from animal organs (e.g. enzymes prepared from pig liver or pig pancreas). Commercially available enzymes are, for example, lipase VII (derived from microorganism of *Candida* sp.; Sigma Co.), lipase AY (derived from microorganism of *Candida* sp.; Amano Pharmaceutical Co.), lipase PS (derived from microorganism of *Pseudomonas* sp.; Amano Pharmaceutical Co.), lipase MF (derived from microorganism of *Pseudomonas* sp.; Amano Pharmaceutical Co.), PLE (prepared from pig liver; Sigma Co.), lipase II (prepared from pig pancreas; Sigma Co.) or lipoprotein lipase (prepared from pig pancreas; Tokyo Kasei Kogyo Co.).

The amount of the enzyme to be used, while depending

on the potency of the enzyme and the amount of the substrate (the compound of Formula (Ia)), is usually 0.1 to 20 parts by weight based on the substrate, and the reaction temperature is from 25 to 50°C, preferably 30 to 40°C.

5 (7) The compound of Formula (Ia) or (Ia') is oxidized using an oxidant such as sodium metaperiodate, hydrogen peroxide, peracetic acid, m-chloroperbenzoic acid or tert-butyl hydroxyperoxide in diethyl ether, methanol, ethanol, methylene chloride, water or a mixture thereof at -20 to
10 50°C to give a PG derivative of Formula (Ic) or (Ic') of the present invention.

 (8) The compound of Formula (Ic) or (Ic') is hydrolyzed in the similar manner as described in the above
15 (6) to give a PG derivative of Formula (Id) or (Id') of the present invention. In addition, the PG derivative of Formula (Ib) or (Ib') is oxidized in the similar manner as described in the above (7) to give a PG derivative of
Formula (Id) or (Id') of the present invention.

Representative compounds of the present invention are
20 described bellow.

Compound	X	Y	m	A	R ¹	R ²	8-position	15-position
1	β-Cl	C≡C	2	SCH ₂	cyclohexyl	tert-butyl	α	α
2	β-Cl	C≡C	0	S(CH ₂) ₃	cyclohexyl	tert-butyl	α	α
3	β-Cl	C≡C	2	SCH ₂	cyclohexyl	cyclohexyl	α	α
4	β-Cl	C≡C	0	S(CH ₂) ₃	cyclohexyl	cyclohexyl	α	α
5	β-Cl	C≡C	2	SCH ₂	cyclohexyl	ethyl	α	α
6	β-Cl	C≡C	2	S(O)CH ₂	cyclohexyl	ethyl	α	α
7	β-Cl	C≡C	2	S(O)CH ₂	cyclohexyl	ethyl	α	β
8	β-Cl	C≡C	2	S(O) ₂ CH ₂	cyclohexyl	ethyl	α	α
9	β-Cl	C≡C	1	SCH ₂	cyclohexyl	methyl	α	α
10	β-Cl	C≡C	1	S(CH ₂) ₂	cyclohexyl	methyl	α	α
11	β-Cl	C≡C	1	S(O)(CH ₂) ₂	cyclohexyl	methyl	α	α
12	β-Cl	C≡C	1	S(CH ₂) ₃	cyclohexyl	methyl	α	α
13	β-Cl	C≡C	0	S(CH ₂) ₃	cyclohexyl	methyl	α	α
14	β-Cl	C≡C	0	S(O)(CH ₂) ₃	cyclohexyl	methyl	α	α
15	β-Cl	C≡C	0	S(O) ₂ (CH ₂) ₃	cyclohexyl	methyl	α	α
16	β-Cl	C≡C	2	SCH ₂	cyclohexyl	hydrogen	α	α
17	β-Cl	C≡C	2	S(O)CH ₂	cyclohexyl	hydrogen	α	α
18	β-Cl	C≡C	2	S(O) ₂ CH ₂	cyclohexyl	hydrogen	α	α
19	β-Cl	C≡C	0	S(CH ₂) ₃	cyclohexyl	hydrogen	α	α
20	β-Cl	C≡C	0	S(O)(CH ₂) ₃	cyclohexyl	hydrogen	α	α
21	β-Cl	C≡C	0	S(O) ₂ (CH ₂) ₃	cyclohexyl	hydrogen	α	α
22	α-Cl	C≡C	2	SCH ₂	cyclohexyl	hydrogen	α	α

23	β -Br	$C\equiv C$	2	SCH_2	cyclohexyl	hydrogen	α	α
24	α -Cl	$C\equiv C$	0	$S(CH_2)_3$	cyclohexyl	hydrogen	α	α
25	α -Br	$C\equiv C$	0	$S(CH_2)_3$	cyclohexyl	hydrogen	α	α
26	F	$C\equiv C$	2	SCH_2	cyclohexyl	hydrogen	α	α
27	β -Cl	$C\equiv C$	2	SCH_2	cyclopentyl	methyl	β	α
28	β -Cl	$C\equiv C$	0	$S(CH_2)_3$	cyclopentyl	methyl	α	α
29	β -Cl	$C\equiv C$	2	SCH_2	cyclopentyl	hydrogen	β	α
30	β -Cl	$C\equiv C$	2	$S(O)CH_2$	cyclopentyl	hydrogen	α	α
31	β -Cl	$C\equiv C$	2	$S(O)_2CH_2$	cyclopentyl	hydrogen	α	α
32	β -Cl	$C\equiv C$	2	SCH_2	cycloheptyl	hydrogen	α	α
33	β -Cl	$C\equiv C$	0	$S(CH_2)_3$	cycloheptyl	hydrogen	α	α
34	β -Cl	$C\equiv C$	2	SCH_2	cyclopentylmethyl	methyl	α	α
35	β -Cl	$C\equiv C$	0	$S(CH_2)_3$	cyclopentylmethyl	methyl	α	α
36	β -Cl	$C\equiv C$	2	SCH_2	cyclopentylmethyl	hydrogen	α	α
37	β -Cl	$C\equiv C$	0	$S(CH_2)_4$	cyclopentylmethyl	hydrogen	α	α
38	α -Cl	$C\equiv C$	2	SCH_2	cyclopentylmethyl	hydrogen	α	α
39	β -Cl	$C\equiv C$	0	$S(CH_2)_3$	cyclohexylmethyl	hydrogen	α	α
40	β -Cl	$C\equiv C$	0	$S(CH_2)_3$	(S)-2-methylhexyl	hydrogen	α	α
41	β -Cl	$C\equiv C$	0	$S(CH_2)_3$	(R)-2-methylhexyl	hydrogen	α	α
42	β -Cl	$C\equiv C$	0	$S(CH_2)_3$	(S)-2,6-dimethyl-5-heptenyl	hydrogen	α	α
43	β -Cl	$C\equiv C$	0	$S(CH_2)_3$	(R)-2,6-dimethyl-5-heptenyl	hydrogen	α	α
44	β -Cl	$C\equiv C$	0	$S(CH_2)_3$	(S)-1-methyl-3-hexynyl	hydrogen	α	α
45	β -Cl	$C\equiv C$	0	$S(CH_2)_3$	(R)-1-methyl-3-hexynyl	hydrogen	α	α
46	β -Cl	$C\equiv C$	2	OCH_2	cyclohexyl	methyl	α	α

47	β -Cl	$C\equiv C$	2	OCH_2	cyclohexyl	methyl	α	β
48	β -Cl	$C\equiv C$	1	OCH_2	cyclohexyl	methyl	α	α
49	β -Cl	$C\equiv C$	1	$O(CH_2)_2$	cyclohexyl	methyl	α	α
50	β -Cl	$C\equiv C$	1	$O(CH_2)_3$	cyclohexyl	methyl	α	α
51	β -Cl	$C\equiv C$	0	$O(CH_2)_3$	cyclohexyl	methyl	α	α
52	β -Cl	$C\equiv C$	2	OCH_2	cyclohexyl	hydrogen	α	α
53	β -Cl	$C\equiv C$	0	$O(CH_2)_3$	cyclohexyl	hydrogen	α	α
54	α -Cl	$C\equiv C$	2	OCH_2	cyclohexyl	hydrogen	α	α
55	β -Br	$C\equiv C$	2	OCH_2	cyclohexyl	hydrogen	α	α
56	α -Br	$C\equiv C$	0	$O(CH_2)_3$	cyclohexyl	hydrogen	α	α
57	F	$C\equiv C$	2	OCH_2	cyclohexyl	hydrogen	α	α
58	β -Cl	$C\equiv C$	2	OCH_2	cyclopentyl	methyl	α	α
59	β -Cl	$C\equiv C$	0	$O(CH_2)_3$	cyclopentyl	methyl	α	α
60	β -Cl	$C\equiv C$	2	OCH_2	cyclopentyl	hydrogen	α	α
61	β -Cl	$C\equiv C$	2	OCH_2	cycloheptyl	hydrogen	α	α
62	β -Cl	$C\equiv C$	0	$O(CH_2)_3$	cycloheptyl	hydrogen	α	α
63	β -Cl	$C\equiv C$	2	OCH_2	cyclopentylmethyl	methyl	β	α
64	β -Cl	$C\equiv C$	0	$O(CH_2)_3$	cyclopentylmethyl	methyl	α	α
65	β -Cl	$C\equiv C$	2	OCH_2	cyclopentylmethyl	hydrogen	β	α
66	β -Cl	$C\equiv C$	0	$O(CH_2)_3$	cyclopentylmethyl	hydrogen	α	α
67	β -Cl	$C\equiv C$	2	OCH_2	cyclopentylmethyl	hydrogen	α	β
68	β -Cl	$C\equiv C$	2	OCH_2	cyclohexylmethyl	hydrogen	α	α
69	β -Cl	$C\equiv C$	0	$O(CH_2)_3$	cyclohexylmethyl	hydrogen	α	α
70	β -Cl	$C\equiv C$	0	$O(CH_2)_3$	(S)-2-methylhexyl	hydrogen	α	α

71	β -Cl	$C\equiv C$	0	$O(CH_2)_3$	(R)-2-methylhexyl	hydrogen	α	α
72	β -Cl	$C\equiv C$	0	$O(CH_2)_3$	(S)-2,6-dimethyl-5-heptenyl	hydrogen	α	α
73	β -Cl	$C\equiv C$	0	$O(CH_2)_3$	(R)-2,6-dimethyl-5-heptenyl	hydrogen	α	α
74	β -Cl	$C\equiv C$	0	$O(CH_2)_3$	(S)-1-methyl-3-hexynyl	hydrogen	α	α
75	β -Cl	$C\equiv C$	0	$O(CH_2)_3$	(R)-1-methyl-3-hexynyl	hydrogen	α	α
76	β -Cl	$C\equiv C$	0	$S(CH_2)_3S$	cyclohexyl	methyl	α	α
77	β -Cl	$C\equiv C$	0	$S(CH_2)_2S$	cyclohexyl	methyl	α	α
78	β -Cl	$C\equiv C$	0	$S(O)(CH_2)_2S(O)$	cyclohexyl	methyl	α	α
79	β -Cl	$C\equiv C$	0	SCH_2S	cyclohexyl	methyl	α	α
80	β -Cl	$C\equiv C$	0	SCH_2SCH_2	cyclohexyl	methyl	α	α
81	β -Cl	$C\equiv C$	0	$S(O)_2CH_2S(O)_2CH_2$	cyclohexyl	methyl	α	α
82	β -Cl	$C\equiv C$	1	SCH_2S	cyclohexyl	methyl	α	α
83	β -Cl	$C\equiv C$	1	$S(CH_2)_2S$	cyclohexyl	methyl	α	α
84	β -Cl	$C\equiv C$	0	$S(CH_2)_2O$	cyclohexyl	methyl	α	α
85	β -Cl	$C\equiv C$	0	$S(CH_2)_3O$	cyclohexyl	methyl	α	α
86	β -Cl	$C\equiv C$	0	$S(O)(CH_2)_2O$	cyclohexyl	methyl	α	α
87	β -Cl	$C\equiv C$	0	$S(O)_2(CH_2)_2O$	cyclohexyl	methyl	α	α
88	β -Cl	$C\equiv C$	0	$S(CH_2)_3S$	cyclohexyl	hydrogen	α	α
89	β -Cl	$C\equiv C$	0	$S(CH_2)_2S$	cyclohexyl	hydrogen	α	α
90	β -Cl	$C\equiv C$	0	SCH_2S	cyclohexyl	hydrogen	α	α
91	β -Cl	$C\equiv C$	0	SCH_2SCH_2	cyclohexyl	hydrogen	α	α
92	β -Cl	$C\equiv C$	0	$S(O)(CH_2)_2S(O)$	cyclohexyl	hydrogen	α	α
93	β -Cl	$C\equiv C$	0	$S(CH_2)_2SCH_2$	cyclohexyl	hydrogen	α	α
94	β -Cl	$C\equiv C$	0	$S(O)_2CH_2S(O)_2CH_2$	cyclohexyl	hydrogen	α	α

14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

95	β -Cl	$C\equiv C$	1	SC_2S	cyclohexyl	hydrogen	α
96	β -Cl	$C\equiv C$	1	$S(CH_2)_2S$	cyclohexyl	hydrogen	α
97	β -Cl	$C\equiv C$	0	$S(CH_2)_2O$	cyclohexyl	hydrogen	α
98	β -Cl	$C\equiv C$	0	$S(CH_2)_3O$	cyclohexyl	hydrogen	α
99	β -Cl	$C\equiv C$	0	$S(O)(CH_2)_2O$	cyclohexyl	hydrogen	α
100	β -Cl	$(E)CH=CH$	2	SC_2	cyclohexyl	methyl	α
101	β -Cl	$(E)CH=CH$	2	SC_2	cyclohexyl	hydrogen	α
102	β -Cl	$(E)CH=CH$	0	$S(CH_2)_3$	cyclohexyl	methyl	α
103	β -Cl	$(E)CH=CH$	0	$S(CH_2)_3$	cyclohexyl	hydrogen	α
104	β -Cl	$(E)CH=CH$	0	$S(O)(CH_2)_3$	cyclohexyl	hydrogen	α
105	β -Cl	$(E)CH=CH$	0	$S(O)_2(CH_2)_3$	cyclohexyl	hydrogen	α
106	β -Cl	$(E)CH=CH$	0	$S(CH_2)_2S$	cyclohexyl	methyl	α
107	β -Cl	$(E)CH=CH$	0	$S(CH_2)_2S$	cyclohexyl	hydrogen	α
108	β -Cl	$(E)CH=CH$	0	$S(O)(CH_2)_2S(O)$	cyclohexyl	hydrogen	α
109	β -Cl	$(E)CH=CH$	0	$S(O)_2(CH_2)_2S(O)_2$	cyclohexyl	hydrogen	α
110	β -Cl	$(E)CH=CH$	2	OCH_2	cyclohexyl	methyl	α
111	β -Cl	$(E)CH=CH$	2	OCH_2	cyclohexyl	hydrogen	α
112	β -Cl	$(E)CH=CH$	0	$S(CH_2)_2O$	cyclohexyl	methyl	α
113	β -Cl	$(E)CH=CH$	0	$S(CH_2)_2O$	cyclohexyl	hydrogen	α
114	β -Cl	$(E)CH=CH$	0	$S(O)(CH_2)_2O$	cyclohexyl	hydrogen	α
115	β -Cl	$(E)CH=CH$	0	$S(O)_2(CH_2)_2O$	cyclohexyl	hydrogen	α
116	β -Cl	$(E)CH=CH$	0	$S(CH_2)_3$	cyclopentylmethyl	hydrogen	α
117	β -Cl	$(E)CH=CH$	0	$S(CH_2)_2S$	cyclopentylmethyl	hydrogen	α
118	β -Cl	$(E)CH=CH$	0	$S(CH_2)_2O$	cyclopentylmethyl	hydrogen	α

119	β -Cl	(Z)CH=CH	0	$S(CH_2)_3$	cyclohexyl	hydrogen	α	α
120	β -Cl	(Z)CH=CH	0	$S(CH_2)_2S$	cyclohexyl	hydrogen	α	α
121	β -Cl	(Z)CH=CH	0	$S(CH_2)_2O$	cyclohexyl	hydrogen	α	α
122	β -Cl	CH_2CH_2	2	SCH_2	cyclohexyl	methyl	α	α
123	β -Cl	CH_2CH_2	2	SCH_2	cyclohexyl	hydrogen	α	α
124	β -Cl	CH_2CH_2	0	$S(CH_2)_3$	cyclohexyl	methyl	α	α
125	β -Cl	CH_2CH_2	0	$S(O)(CH_2)_3$	cyclohexyl	methyl	α	α
126	β -Cl	CH_2CH_2	0	$S(O)_2(CH_2)_3$	cyclohexyl	methyl	α	α
127	β -Cl	CH_2CH_2	0	$S(CH_2)_3$	cyclohexyl	hydrogen	α	α
128	β -Cl	CH_2CH_2	0	$S(O)(CH_2)_3$	cyclohexyl	hydrogen	α	α
129	β -Cl	CH_2CH_2	0	$S(O)_2(CH_2)_3$	cyclohexyl	hydrogen	α	α
130	β -Cl	CH_2CH_2	0	$S(CH_2)_2S$	cyclohexyl	methyl	α	α
131	β -Cl	CH_2CH_2	0	$S(CH_2)_2S$	cyclohexyl	hydrogen	α	α
132	β -Cl	CH_2CH_2	0	$S(O)(CH_2)_2S(O)$	cyclohexyl	hydrogen	α	α
133	β -Cl	CH_2CH_2	0	$S(O)_2(CH_2)_2S(O)_2$	cyclohexyl	hydrogen	α	α
134	β -Cl	CH_2CH_2	2	OCH_2	cyclohexyl	methyl	α	α
135	β -Cl	CH_2CH_2	2	OCH_2	cyclohexyl	hydrogen	α	α
136	β -Cl	CH_2CH_2	0	$S(CH_2)_2O$	cyclohexyl	methyl	α	α
137	β -Cl	CH_2CH_2	0	$S(CH_2)_2O$	cyclohexyl	hydrogen	α	α
138	β -Cl	CH_2CH_2	0	$S(O)(CH_2)_2O$	cyclohexyl	hydrogen	α	α
139	β -Cl	CH_2CH_2	0	$S(O)_2(CH_2)_2O$	cyclohexyl	hydrogen	α	α
140	β -Cl	CH_2CH_2	0	$S(CH_2)_3O$	cyclohexyl	methyl	α	α
141	β -Cl	CH_2CH_2	0	$S(CH_2)_3O$	cyclohexyl	hydrogen	α	α
142	β -Cl	CH_2CH_2	0	$S(CH_2)_2O$	cyclohexyl	tert-butyl	α	α

119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142

143	β -Cl	CH_2CH_2	0	SCH_2OCH_2	cyclohexyl	methyl	α	α
144	β -Cl	CH_2CH_2	0	SCH_2OCH_2	cyclohexyl	hydrogen	α	α
145	β -Cl	CH_2CH_2	0	$\text{S}(\text{CH}_2)_2\text{O}$	cyclopentyl	methyl	α	α
146	β -Cl	CH_2CH_2	0	$\text{S}(\text{CH}_2)_2\text{O}$	cyclopentyl	hydrogen	α	α
147	β -Cl	CH_2CH_2	0	$\text{S}(\text{CH}_2)_2\text{O}$	cycloheptyl	methyl	α	α
148	β -Cl	CH_2CH_2	0	$\text{S}(\text{CH}_2)_2\text{O}$	cycloheptyl	hydrogen	α	α
149	β -Cl	CH_2CH_2	0	$\text{S}(\text{CH}_2)_2\text{O}$	cyclohexylmethyl	hydrogen	α	α
150	β -Br	CH_2CH_2	0	$\text{S}(\text{CH}_2)_2\text{O}$	n-pentyl	hydrogen	β	α
151	β -Cl	CH_2CH_2	0	$\text{S}(\text{CH}_2)_2\text{O}$	n-pentyl	hydrogen	α	α
152	α -Cl	CH_2CH_2	0	$\text{S}(\text{CH}_2)_2\text{O}$	n-pentyl	hydrogen	α	α
153	β -Cl	CH_2CH_2	0	SCH_2SCH_2	cyclohexyl	methyl	α	α
154	β -Cl	CH_2CH_2	0	SCH_2SCH_2	cyclohexyl	hydrogen	α	α
155	β -Cl	CH_2CH_2	0	$\text{S}(\text{CH}_2)_2\text{S}$	cyclopentyl	methyl	α	α
156	β -Cl	CH_2CH_2	0	$\text{S}(\text{CH}_2)_2\text{S}$	cyclopentyl	hydrogen	α	α
157	β -Cl	CH_2CH_2	0	$\text{S}(\text{CH}_2)_2\text{S}$	cycloheptyl	methyl	α	α
158	β -Cl	CH_2CH_2	0	$\text{S}(\text{CH}_2)_2\text{S}$	cycloheptyl	hydrogen	α	α
159	β -Cl	CH_2CH_2	0	$\text{S}(\text{CH}_2)_2\text{S}$	cyclohexylmethyl	methyl	α	α
160	β -Cl	CH_2CH_2	0	$\text{S}(\text{CH}_2)_2\text{S}$	cyclohexylmethyl	hydrogen	α	α
161	β -Cl	CH_2CH_2	0	$\text{S}(\text{CH}_2)_2\text{S}$	n-pentyl	hydrogen	β	β
162	α -Cl	CH_2CH_2	0	$\text{S}(\text{CH}_2)_2\text{S}$	n-pentyl	hydrogen	α	α
163	β -Cl	$(Z)\text{CH}=\text{CH}$	0	$\text{S}(\text{CH}_2)_2\text{O}$	cyclohexyl	methyl	α	α
164	F	$(E)\text{CH}=\text{CH}$	0	$\text{S}(\text{CH}_2)_2\text{O}$	cyclohexyl	methyl	α	α
165	F	$(E)\text{CH}=\text{CH}$	0	$\text{S}(\text{CH}_2)_2\text{O}$	cyclohexyl	hydrogen	α	α
166	β -Cl	$(E)\text{CH}=\text{CH}$	0	$\text{S}(\text{CH}_2)_2\text{O}$	cyclopentyl	hydrogen	α	β

167	β -Cl	(E)CH=CH	0	S(CH ₂) ₂ O	(R)-2-methylhexyl	hydrogen	α	α
168	β -Cl	(E)CH=CH	0	S(CH ₂) ₂ O	(S)-2-methylhexyl	hydrogen	α	α
169	β -Cl	(E)CH=CH	0	S(CH ₂) ₂ O	(R)-1-methyl-3-hexynyl	hydrogen	α	α
170	β -Cl	(E)CH=CH	0	S(CH ₂) ₂ O	(S)-1-methyl-3-hexynyl	hydrogen	α	α
171	β -Cl	(Z)CH=CH	0	S(CH ₂) ₂ S	cyclohexyl	methyl	α	α
172	β -Cl	(E)CH=CH	0	S(CH ₂) ₂ S	cyclopentyl	hydrogen	α	β
173	β -Cl	(E)CH=CH	0	S(CH ₂) ₂ S	(R)-2-methylhexyl	hydrogen	α	α
174	β -Cl	(E)CH=CH	0	S(CH ₂) ₂ S	(S)-2-methylhexyl	hydrogen	α	α
175	β -Cl	(E)CH=CH	0	S(O)(CH ₂) ₂ S(O)	(R)-2-methylhexyl	hydrogen	α	α
176	β -Cl	(E)CH=CH	0	S(O)(CH ₂) ₂ S(O)	(S)-2-methylhexyl	hydrogen	α	α
177	β -Cl	(E)CH=CH	0	S(CH ₂) ₂ S	(R)-1-methyl-3-hexynyl	hydrogen	α	α
178	β -Cl	(E)CH=CH	0	S(CH ₂) ₂ S	(S)-1-methyl-3-hexynyl	hydrogen	α	α
179	α -Cl	CH \equiv CH	0	S(CH ₂) ₂ O	cyclohexyl	methyl	α	α
180	α -Cl	CH \equiv CH	0	S(CH ₂) ₂ O	cyclohexyl	hydrogen	α	α
181	β -Cl	CH \equiv CH	0	S(CH ₂) ₂ O	cyclopentyl	hydrogen	α	α
182	β -Cl	CH \equiv CH	0	S(CH ₂) ₂ O	cycloheptyl	hydrogen	α	α
183	β -Cl	CH \equiv CH	0	S(CH ₂) ₂ O	cyclopentylmethyl	hydrogen	α	α
184	β -Cl	CH \equiv CH	0	S(CH ₂) ₂ O	cyclohexylmethyl	hydrogen	α	α
185	β -Cl	CH \equiv CH	0	S(CH ₂) ₂ O	(R)-2-methylhexyl	hydrogen	α	α
186	β -Cl	CH \equiv CH	0	S(CH ₂) ₂ O	(S)-2-methylhexyl	hydrogen	α	α
187	β -Cl	CH \equiv CH	0	S(CH ₂) ₂ O	(R)-2,6-dimethyl-5-heptenyl	hydrogen	α	α
188	β -Cl	CH \equiv CH	0	S(CH ₂) ₂ O	(S)-2,6-dimethyl-5-heptenyl	hydrogen	α	α
189	β -Cl	CH \equiv CH	0	S(CH ₂) ₂ S(O)	cyclohexyl	methyl	α	α
190	β -Cl	CH \equiv CH	0	S(CH ₂) ₂ S(O)	cyclohexyl	hydrogen	α	α

191	β -Cl	CH \equiv CH	0	S(O) ₂ (CH ₂) ₂ S(O) ₂	cyclohexyl	methyl	α
192	β -Cl	CH \equiv CH	0	S(O) ₂ (CH ₂) ₂ S(O) ₂	cyclohexyl	hydrogen	α
193	α -Cl	CH \equiv CH	0	S(CH ₂) ₂ S	cyclohexyl	methyl	α
194	α -Cl	CH \equiv CH	0	S(CH ₂) ₂ S	cyclohexyl	hydrogen	α
195	β -Cl	CH \equiv CH	0	S(CH ₂) ₂ S	cyclopentyl	hydrogen	α
196	β -Cl	CH \equiv CH	0	S(CH ₂) ₂ S	cycloheptyl	hydrogen	α
197	β -Cl	CH \equiv CH	0	S(CH ₂) ₂ S	cyclopentylmethyl	hydrogen	α
198	β -Cl	CH \equiv CH	0	S(CH ₂) ₂ S	cyclohexylmethyl	hydrogen	α
199	β -Cl	CH \equiv CH	0	S(CH ₂) ₂ S	(R)-2-methylhexyl	hydrogen	α
200	β -Cl	CH \equiv CH	0	S(CH ₂) ₂ S	(S)-2-methylhexyl	hydrogen	α
201	β -Cl	CH \equiv CH	0	S(CH ₂) ₂ S	(R)-2,6-dimethyl-5-heptenyl	hydrogen	α
202	β -Cl	CH \equiv CH	0	S(CH ₂) ₂ S	(S)-2,6-dimethyl-5-heptenyl	hydrogen	α
203	α -Cl	CH \equiv CH	0	S(CH ₂) ₂ S	(R)-2-methylhexyl	hydrogen	α
204	α -Cl	CH \equiv CH	0	S(CH ₂) ₂ S	(S)-2-methylhexyl	hydrogen	β
205	F	CH \equiv CH	0	S(CH ₂) ₂ S	(R)-2,6-dimethyl-5-heptenyl	hydrogen	α
206	F	CH \equiv CH	0	S(CH ₂) ₂ S	(S)-2,6-dimethyl-5-heptenyl	hydrogen	α

(E)CH=CH: trans-vinylene (Z)CH=CH: cis-vinylene, 8 position: binding of the carbon atom at the 7-position and the carbon atom at the 8-position, 15 position: binding of the carbon atom and the hydroxyl group at the 15-position.

11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

The compounds of the present invention can be administered systemically or topically, or orally or parenterally (intravenously) in conventional dosage forms. For example, the dosage form for oral administration includes tablets, powders, granules, dusting powders, capsules, solutions, emulsions or suspensions, each of which can be prepared according to conventional methods. The dosage form for intravenous administration includes aqueous or non-aqueous solutions, emulsions, suspensions or solid preparations to be dissolved in a solvent for injection immediately before use. Furthermore, the compounds of the present invention can be formulated into the form of inclusion compounds with α -, β - or γ -cyclodextrin, or methylated cyclodextrin. In addition, the compounds of the present invention can be administered by injection in the form of aqueous or non-aqueous solutions, emulsions, suspensions, etc. The dose is varied by the age, body weight, etc., but it is from 1 ng to 1 mg/day per adult, which can be administered in a single dose or divided doses.

BEST MODE FOR CARRYING OUT THE INVENTION

The present invention is illustrated in more details by the following examples and experiment, but it is not limited by these descriptions.

Example 1

6-Thia-9-deoxy-9 β -chloro-16,17,18,19,20-pentanor-15-cyclohexyl-13,14-didehydro-PGF₁ α methyl ester (Compound 13)

(1) In toluene (80 ml) was dissolved (3S)-3-

(tert-butyldimethylsiloxy)-3-cyclohexylprop-1-yne (6.58 g),
 and n-butyl lithium (3.0 M, hexane solution, 8.0 ml) was
 added at 0°C, followed by stirring at the same temperature
 for 30 minutes. To the solution was added diethylaluminum
 5 chloride (0.95 M, hexane solution, 29.0 ml) at 0°C,
 followed by stirring at room temperature for 30 minutes.
 To the solution was added (4R)-2-(N,N-diethylamino)methyl-
 4-(tert-butyldimethylsiloxy)cyclopent-2-en-1-one (0.25 M,
 toluene solution, 80.0 ml) at room temperature, followed by
 10 stirring for 15 minutes. The reaction solution, while
 stirring, was added to a mixture of hexane (190 ml), a
 saturated aqueous ammonium chloride solution (190 ml) and
 an aqueous hydrochloric acid solution (3 M, 56 ml), and the
 organic layer was separated and washed with a saturated
 15 aqueous sodium bicarbonate solution (50 ml). The resulting
 organic layer was dried over anhydrous magnesium sulfate,
 filtered and concentrated, and the resulting residue was
 purified by a silica gel column chromatography (developing
 solvent; hexane : ether =10:1) to give (3R,4R)-2-methylene-
 20 3-[(3S)-3-(tert-butyldimethylsiloxy)-3-cyclohexylprop-1-
 ynyl]-4-(tert-butyldimethylsiloxy)cyclopentan-1-one (7.92
 g).

¹H-NMR(CDCl₃, 200MHz) δppm ;
 0.07, 0.08 and 0.12(3s, 12H), 0.88(s, 18H), 0.92-1.92(m, 11H),
 2.32(dd, J=17.8, 7.4Hz, 1H), 2.71(dd, J=17.8, 6.5Hz, 1H), 3.48-
 25 3.58(m, 1H), 4.11(dd, J=6.2, 1.4Hz, 1H), 4.20-4.32(m, 1H),
 5.55(d, J=2.6Hz, 1H), 6.13(d, J=3.0Hz, 1H)
 IR(neat) cm⁻¹ ;

2930, 2850, 1375, 1640, 1470, 1380, 1255, 830, 770

(2) To a toluene solution (32 ml) of the compound obtained in the above (1) (3.86 g) and methyl 5-mercaptopentanoate (1.64 g) was added triethyl borane (1.0 M, hexane solution, 0.81 ml) under an argon atmosphere at 0°C, followed by allowing to stand at the same temperature overnight. The reaction solution was purified by a silica gel column chromatography to give 6-thia-16,17,18,19,20-pentananor-15-cyclohexyl-13,14-didehydro-PGE₁ methyl ester 11,15-bis(tert-butyldimethylsilyl ether) (1.02 g).

 $^1\text{H-NMR}(\text{CDCl}_3, 200\text{MHz}) \delta \text{ppm};$

0.08(s, 3H), 0.09(s, 3H), 0.10(s, 3H), 0.13(s, 3H), 0.71-
1.93(m, 15H), 0.89(s, 9H), 0.90(s, 9H), 2.22(dd, J=18.2, 5.9Hz, 1
H), 2.33(t, J=7.3Hz, 2H), 2.40-2.59(m, 1H),
15 2.53(t, J=7.0Hz, 2H), 2.71(dd, J=18.2, 6.0Hz, 1H), 2.73-
2.96(m, 2H), 3.09-3.22(m, 1H), 3.67(s, 3H),
4.08(dd, J=6.3, 1.6Hz, 1H), 4.29-4.41(m, 1H)
IR(neat) cm^{-1} ;

20 2951,2929,2855,2236,1746,1472,1463,1451,1406,1361,1252,
1202,1109,1065,1006,939,898,837,778,669,587

(3) A methyl alcohol solution (12.8 ml) of the compound obtained in the above (2) (800 mg) was cooled to 0°C, and potassium borohydride (138 mg) was added, followed by stirring for 40 minutes. A saturated aqueous ammonium chloride solution was added, followed by extraction with ethyl acetate. The organic layer was washed with a saturated aqueous ammonium chloride solution and a saturated aqueous sodium chloride solution, dried over

anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by a silica gel column chromatography (developing solvent; n-hexane : ethyl acetate =7:1 to 4:1) to give 6-thia-16,17,18,19,20-pentano-15-cyclohexyl-13,14-didehydro-PGF₁α methyl ester 11,15-bis(tert-butyltrimethylsilyl ether) (500 mg) and 6-thia-16,17,18,19,20-pentano-15-cyclohexyl-13,14-didehydro-PGF₁β methyl ester 11,15-bis(tert-butyltrimethylsilyl ether) (248 mg).

6-Thia-16,17,18,19,20-pentano-15-cyclohexyl-13,14-didehydro-PGF₁α methyl ester 11,15-bis(tert-butyltrimethylsilyl ether)

¹H-NMR(CDCl₃, 200MHz)δppm ;

0.08(s, 3H), 0.09(s, 3H), 0.10(s, 6H), 0.84-2.24(m, 18H), 0.89(s, 9H), 0.90(s, 9H), 2.34(t, J=7.4Hz, 2H), 2.50-2.64(m, 4H), 2.74-2.88(m, 2H), 3.67(s, 3H), 4.08(dd, J=5.9, 1.8Hz, 1H), 4.18-4.33(m, 1H)

IR(neat) cm⁻¹ ;

3435, 2928, 2854, 2232, 1741, 1471, 1462, 1450, 1385, 1361, 1251, 1205, 1110, 1062, 1005, 925, 898, 836, 776, 669

6-Thia-16,17,18,19,20-pentano-15-cyclohexyl-13,14-didehydro-PGF₁β methyl ester 11,15-bis(tert-butyltrimethylsilyl ether)

¹H-NMR(CDCl₃, 200MHz)δppm ;

0.07(s, 3H), 0.08(s, 6H), 0.11(s, 3H), 0.82-2.08(m, 18H), 0.88(s, 9H), 0.90(s, 9H), 2.27-2.40(m, 3H), 2.47(dd, J=13.2, 10.3Hz, 1H), 2.58(t, J=6.9Hz, 2H),

6-Thia-9-deoxy-9 β -chloro-16,17,18,19,20-pentano-15-cyclohexyl-13,14-didehydro-PGF₁ α (Compound 19)

To a methyl alcohol (10.6 ml) - water (1.06 ml) solution of the compound obtained in Example 1 (133 mg) was added lithium hydroxide monohydrate (67 mg), followed by stirring at room temperature overnight. The mixture was made weakly acidic with 1 M hydrochloric acid and extracted with ethyl acetate, and the extract was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the resulting crude product was purified by a silica gel column chromatography (developing solvent; ethyl acetate) to give the title compound (120 mg).

¹H-NMR(CDCl₃, 200MHz) δ ppm ;
 0.92-2.01(m, 21H), 2.14-3.06(m, 9H),
 2.72(dd, J=13.7, 5.3Hz, 1H), 2.94(dd, J=13.7, 4.9Hz, 1H), 4.09-4.27(m, 2H), 4.34-4.47(m, 1H)
 IR(neat) cm⁻¹ ;
 3368, 2927, 2852, 2236, 1708, 1450, 1412, 1278, 1082, 1007, 893, 847, 758

Example 3

4-Oxa-9-deoxy-9 β -chloro-16,17,18,19,20-pentano-15-cyclohexyl-13,14-didehydro-PGF₁ α methyl ester (Compound 46)

(1) To a toluene solution (13.5 ml) of the compound obtained in Example 1(1) (1.60 g) and methyl 4-oxa-6-iodohexanoate (2.16 g) were added tributyltin hydride (2.25 ml) and triethyl borane (1.0 M, hexane solution, 0.34 ml)

under argon atmosphere at 0°C, followed by allowing to stand at the same temperature overnight. The reaction solution was purified by a silica gel column chromatography to give 4-oxa-16,17,18,19,20-pentanor-15-cyclohexyl-13,14-didehydro-PGE₁ methyl ester 11,15-bis(tert-butylldimethylsilyl ether) (1.22 g).

¹H-NMR(CDCl₃,200MHz)δppm;

0.08(s,3H),0.09(s,3H),0.10(s,3H),0.12(s,3H),0.78-1.94(m,15H),0.89(s,9H),0.90(s,9H),2.07-2.30(m,1H),
2.17(dd,J=18.2,7.0Hz,1H), 2.52-2.77(m,2H),
2.61(t,J=6.4Hz,2H),3.44(t,J=6.2Hz,2H),3.60-3.84(m,2H),
3.70(s,3H),4.08(dd,J=6.3,1.4Hz,1H),4.22-4.36(m,1H)

IR(neat) cm⁻¹;

2952,2929,2856,2235,1746,1472,1463,1437,1406,1361,1252,
1196,1176,1104,1006,939,898,837,778,669

(2) Following the substantially same manner as in Example 1(3) using the compound obtained in the above (1), thereby the compounds described below were obtained.

4-Oxa-16,17,18,19,20-pentanor-15-cyclohexyl-13,14-didehydro-PGF_{1α} methyl ester 11,15-bis(tert-butylldimethylsilyl ether)

¹H-NMR(CDCl₃,200MHz)δppm;

0.08(s,3H),0.09(2s,6H),0.10(s,3H),0.78-2.11(m,18H),
0.88(s,9H),0.90(s,9H),2.41-2.52(m,1H),2.58(t,J=6.6Hz,2H),
2.63(d,J=8.8Hz,1H),3.41-3.54(m,2H),3.69(s,3H),
3.70(t,J=6.5Hz,2H),4.02-4.31(m,2H),
4.07(dd,J=6.2,2.0Hz,1H)

IR(neat) cm⁻¹;

3468,2929,2855,2229,1745,1472,1463,1451,1361,1337,1252,
1196,1106,1072,1005,963,939,898,836,776,668

5 butyldimethylsilyl ether)

0.07(s, 3H), 0.08(s, 6H), 0.11(s, 3H), 0.78-1.95(m, 18H),
0.88(s, 9H), 0.90(s, 9H), 2.21(ddd, J=9.7, 6.6, 1.6Hz, 1H),
2.25(d, J=4.2Hz, 1H), 2.59(t, J=6.4Hz, 2H), 3.50(t, J=5.6Hz, 2H),
3.70(t, J=6.4Hz, 2H), 3.70(s, 3H), 3.90-4.04(m, 1H),
4.08(dd, J=6.2, 1.6Hz, 1H), 4.16-4.30(m, 1H)

3459,2929,2855,2229,1745,1472,1463,1451,1406,1361,1337,
1252,1177,1110,1068,1006,927,898,836,777,669

(3) Following the substantially same manner as in Example 1(4) using 4-oxa-16,17,18,19,20-pentanol-15-cyclohexyl-13,14-didehydro-PGF₁α methyl ester 11,15-bis(tert-butyldimethylsilyl ether) obtained in the above (2), thereby 4-oxa-9-deoxy-9β-chloro-16,17,18,19,20-pentanol-15-cyclohexyl-13,14-didehydro-PGF₁α methyl ester 11,15-bis(tert-butyldimethylsilyl ether) was obtained.

0.07(s, 3H), 0.08(s, 6H), 0.10(s, 3H), 0.80-2.20(m, 18H),
0.88(s, 9H), 0.90(s, 9H), 2.29(ddd, J=8.8, 4.8, 1.8Hz, 1H),
2.59(t, J=6.5Hz, 2H), 3.46(t, J=5.9Hz, 2H), 3.70(t, J=6.5Hz, 2H),
3.70(s, 3H), 3.88-4.03(m, 1H), 4.07(dd, J=6.3, 1.8Hz, 1H), 4.20-
4.31(m, 1H)

IR(neat) cm^{-1} ;

2951,2929,2856,2229,1745,1472,1463,1451,1438,1361,1252,
1195,1176,1109,1072,1006,962,939,898,836,814,777,669

(4) Following the substantially same manner as in Example 1(5) using the compound obtained in the above (3),

$$^1\text{H-NMR}(\text{CDCl}_3, 300\text{MHz}) \delta \text{ppm};$$

0.84-1.91(m, 15H), 2.04-2.37(m, 4H), 2.08(d, J=5.8Hz, 1H),
2.10(d, J=3.6Hz, 1H), 2.59(t, J=6.4Hz, 2H), 3.48(dt, J=2.0, 6.2H
z, 2H), 3.70(t, J=6.4Hz, 2H), 3.70(s, 3H), 3.91-4.01(m, 1H),
4.16(dt, J=1.8, 5.8Hz, 1H), 4.32-4.42(m, 1H)

3400,2927,2853,2229,1739,1439,1370,1331,1262,1198,1178,
1115,1072,1017,893,847,757

15 4-Oxa-9-deoxy-9 β -chloro-16,17,18,19,20-pentanor-15-cyclohexyl-13,14-didehydro-PGF₁ α (Compound 52)

To an aqueous suspension (44 ml) of lipase PS (2.27 g) were added an acetone solution (4.34 ml) of the compound obtained in Example 3 (81 mg) and phosphate buffer solution (pH=7.0, 0.2 M, 2.2 ml), followed by stirring at 30°C overnight. The reaction solution was filtered, and the filtrate was made acidic with 1 M hydrochloric acid, salted out with ammonium sulfate and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the resulting crude product was purified by a silica gel column chromatography (developing

solvent; ethyl acetate) to give the title compound (75 mg).

$^1\text{H-NMR}(\text{CDCl}_3, 300\text{MHz})\delta\text{ppm};$

0.80-1.91(m, 18H), 2.13-2.36(m, 4H), 2.59(t, J=6.0Hz, 2H),

3.44-3.61(m, 2H), 3.72(t, J=6.0Hz, 2H), 3.92-4.01(m, 1H),

5 4.19(dd, J=6.1, 1.9Hz, 1H), 4.31-4.41(m, 1H)

IR(neat) cm^{-1} ;

3367, 2928, 2854, 2235, 1717, 1450, 1261, 1196, 1114, 1009, 893,

832, 756, 688

Example 5

10 4-Thia-9-deoxy-9 β -chloro-16,17,18,19,20-pentanor-15-cyclohexyl-13,14-didehydro-PGF $_1\alpha$ ethyl ester (Compound 5)

(1) Following the substantially same manner as in Example 3(1) using ethyl 4-thia-6-iodohexanoate in place of methyl 4-oxa-6-iodohexanoate in Example 3(1), thereby 4-thia-16,17,18,19,20-pentanor-15-cyclohexyl-13,14-didehydro-PGE $_1$ ethyl ester 11,15-bis(tert-butyldimethylsilyl ether) was obtained.

$^1\text{H-NMR}(\text{CDCl}_3, 200\text{MHz})\delta\text{ppm};$

0.08(s, 3H), 0.09(s, 3H), 0.10(s, 3H), 0.12(s, 3H), 0.78-

20 1.96(m, 15H), 0.89(s, 9H), 0.90(s, 9H), 1.27(t, J=7.1Hz, 3H),

2.08-2.36(m, 1H), 2.17(dd, J=18.3, 6.9Hz, 1H), 2.48-

2.93(m, 8H), 4.05-4.36(m, 2H), 4.16(q, J=7.1Hz, 2H)

IR(neat) cm^{-1} ;

2929, 2855, 1745, 1472, 1463, 1450, 1407, 1372, 1342, 1250, 1100,

25 1072, 1006, 939, 898, 884, 838, 778, 669, 586, 428

(2) Following the substantially same manner as in Example 1(3) using the compound obtained in the above (1), thereby the compounds described below were obtained.

4-Thia-16,17,18,19,20-pentanol-15-cyclohexyl-13,14-didehydro-PGF₁α ethyl ester 11,15-bis(tert-butyldimethylsilyl ether)

¹H-NMR(CDCl₃,200MHz)δppm ;

5 0.08(s,3H),0.09(s,3H),0.10(s,3H),0.11(s,3H),0.81-2.09(m,19H),0.89(s,9H),0.90(s,9H),1.27(t,J=7.1Hz,3H),2.32-2.92(m,7H),4.04-4.23(m,1H),4.08(dd,J=6.4,2.0Hz,1H),4.16(q,J=7.1Hz,2H), 4.25-4.33(m,1H)

IR(neat) cm⁻¹ :

10 3462,2928,2854,1736,1701,1450,1371,1249,1100,898,836,776

4-Thia-16,17,18,19,20-pentanol-15-cyclohexyl-13,14-didehydro-PGF₁β ethyl ester 11,15-bis(tert-butyldimethylsilyl ether)

¹H-NMR(CDCl₃,200MHz)δppm ;

15 0.07(s,3H),0.08(s,6H),0.11(s,3H),0.82-1.98(m,19H),0.88(s,9H),0.90(s,9H),1.27(t,J=7.1Hz,3H),2.17-2.86(m,5H),2.60(t,6.8Hz,2H),3.93-4.28(m,2H),4.08(dd,J=6.4,1.8Hz,1H),4.16(q,J=7.1Hz,2H)

IR(neat) :

20 3458,2929,2854,1739,1639,1472,1371,1342,1250,1065,898,837,777,670

(3) Following the substantially same manner as in Example 1(4) using 4-thia-16,17,18,19,20-pentanol-15-cyclohexyl-13,14-didehydro-PGF₁α ethyl ester 11,15-bis(tert-butyldimethylsilyl ether) obtained in the above (2), thereby 4-thia-9-deoxy-9β-chloro-16,17,18,19,20-pentanol-15-cyclohexyl-13,14-didehydro-PGF₁α ethyl ester 11,15-bis(tert-butyldimethylsilyl ether) was obtained.

$^1\text{H-NMR}(\text{CDCl}_3, 300\text{MHz})\delta\text{ppm};$

0.07(s, 3H), 0.08(s, 6H), 0.09(s, 3H), 0.82-1.90(m, 16H),
 0.88(s, 9H), 0.90(s, 9H), 1.27(t, J=7.2Hz, 3H), 2.05-
 2.18(m, 2H), 2.29(ddd, J=9.0, 4.8, 1.8Hz, 1H), 2.52-
 5 2.64(m, 4H), 2.74-2.83(m, 2H), 3.90-4.01(m, 1H),
 4.08(dd, J=6.2, 1.6Hz, 1H), 4.16(q, J=7.2Hz, 2H), 4.21-
 4.28(m, 1H)

IR(neat) cm^{-1} :

2929, 2855, 2229, 1739, 1471, 1371, 1342, 1251, 1138, 1099, 1068,
 10 1006, 959, 898, 836, 777, 668

(4) Following the substantially same manner as in
 Example 1(5) using the compound obtained in the above (3),
 thereby the title compound was obtained.

$^1\text{H-NMR}(\text{CDCl}_3, 300\text{MHz})\delta\text{ppm};$

15 0.95-1.91(m, 16H), 1.27(t, J=7.2Hz, 3H), 2.09-2.36(m, 4H),
 2.32(ddd, J=9.9, 6.4, 1.9Hz, 1H), 2.50-2.67(m, 4H), 2.75-
 2.84(m, 2H), 3.88-4.01(m, 1H), 4.07-4.23(m, 1H),
 4.16(q, J=7.2Hz, 2H), 4.31-4.42(m, 1H)

IR(neat):

20 3400, 2927, 2852, 2229, 1734, 1449, 1372, 1342, 1297, 1247, 1183,
 1149, 1085, 1014, 892, 763, 685

Example 6

4-Thia-9-deoxy-9 β -chloro-16,17,18,19,20-pentanor-15-
 cyclohexyl-13,14-didehydro-PGF $_1\alpha$ (Compound 16)

25 Following the substantially same manner as in Example
 4 using the compound obtained in Example 5, thereby the
 title compound was obtained.

$^1\text{H-NMR}(\text{CDCl}_3, 300\text{MHz})\delta\text{ppm};$

0.84-1.92(m, 16H), 2.09-3.00(m, 12H), 3.89-4.01(m, 1H),
4.19(dd, J=6.1, 1.9Hz, 1H), 4.31-4.43(m, 1H)

IR(neat) cm^{-1} :

3367,2927,2853,2235,1712,1449,1415,1334,1260,1188,1149,
5 1084,1008,948,895,802,758

Example 7

6-Thia-9-deoxy-9 β -chloro-16,17,18,19,20-pentano-15-cyclohexyl-PGF₁ α methyl ester (Compound 102)

(1) (1E,3S)-1-Iodo-3-(tert-butyldimethylsiloxy)-3-cyclohexyl-1-propene (2.66 g) was dissolved in ether (28 ml), tert-butyl lithium (1.7 M, pentane solution, 8.24 ml) was added at -78°C. After stirring at the same temperature for an hour, lithium 2-thienylcyanocuprate (0.25 M, tetrahydrofuran solution, 39.2 ml) was added, followed by stirring at the same temperature for 20 minutes, and (4R)-2-(N,N-diethylamino)methyl-4-(tert-butyldimethylsiloxy)cyclopent-2-en-1-one (0.25 M, ether solution, 28 ml) was added. The temperature was raised to 0°C with stirring over 1.5 hours. To the reaction solution were added hexane (70 ml) and a saturated aqueous ammonium chloride solution (105 ml) and, after extraction with hexane, the extract was washed with a saturated aqueous sodium chloride solution, dried, concentrated and purified by a silica gel column chromatography (developing solvent; n-hexane : ethyl acetate =30:1) to give (3R,4R)-2-methylene-3-[(1E,3S)-3-(tert-butyldimethylsiloxy)-3-cyclohexyl-1-propenyl]-4-(tert-butyldimethylsiloxy)cyclopentan-1-one (910 mg).

$^1\text{H-NMR}(\text{CDCl}_3, 200\text{MHz})\delta\text{ppm};$

0.00(s, 3H), 0.01(s, 3H), 0.04(s, 3H), 0.07(s, 3H), 0.73-
1.89(m, 11H), 0.88(s, 9H), 0.90(s, 9H), 2.33(dd, J=17.9, 6.3Hz,
1H,), 2.65(dd, J=17.9, 6.3Hz, 1H), 3.27-3.91(m, 2H), 4.07-
5 4.20(m, 1H), 5.25(dd, J=2.5, 1.0Hz, 1H), 5.47(ddd, J=15.9, 7.2,
0.8Hz, 1H), 5.61(dd, J=15.5, 5.1Hz, 1H), 6.12(dd, J=2.9, 1.0Hz,
1H)

IR(neat) cm^{-1} ;

2954, 2929, 2856, 1734, 1642, 1472, 1451, 1388, 1361, 1253, 1113,
10 1071, 1006, 973, 943, 923, 900, 837, 776, 690

(2) Following the substantially same manner as in
Example 1(2) using the compound obtained in the above (1)
in place of (3R,4R)-2-methylene-3-[(3S)-3-(tert-
butyldimethylsiloxy)-3-cyclohexylprop-1-ynyl]-4-(tert-
15 butyldimethylsiloxy)cyclopentan-1-one in Example 1(2),
thereby 6-thia-16,17,18,19,20-pentanor-15-cyclohexyl-PGE₁
methyl ester 11,15-bis(tert-butyldimethylsilyl ether) was
obtained.

$^1\text{H-NMR}(\text{CDCl}_3, 200\text{MHz})\delta\text{ppm};$

20 -0.01(s, 3H), 0.04(s, 3H), 0.06(s, 3H), 0.07(s, 3H), 0.70-
1.86(m, 15H), 0.88(s, 9H), 0.90(s, 9H), 2.12-2.94(m, 4H),
2.32(t, J=7.1Hz, 2H), 2.51(t, J=6.9Hz, 2H), 2.72(dd, J=13.1, 4.7
Hz, 1H), 2.87(dd, J=13.1, 5.4Hz, 1H), 3.67(s, 3H), 3.77-
3.90(m, 1H), 4.02-4.20(m, 1H), 5.50(dd, J=15.5, 6.9Hz, 1H),
25 5.62(dd, J=15.5, 5.1Hz, 1H)

IR(neat) cm^{-1} ;

2952, 2930, 2855, 1746, 1740, 1472, 1463, 1451, 1407, 1361, 1252,
1202, 1154, 1116, 1072, 1006, 978, 899, 837, 776, 670

(3) Following the substantially same manner as in Example 1(3) using the compound obtained in the above (2), thereby the compounds described below were obtained.

6-Thia-16,17,18,19,20-pentanol-15-cyclohexyl-PGF₁α
5 methyl ester 11,15-bis(tert-butyldimethylsilyl ether)

¹H-NMR(CDCl₃,200MHz)δppm ;

-0.01(s,3H),0.03(s,3H),0.05(s,6H),0.72-
2.08(m,19H),0.87(s,9H),0.89(s,9H),2.33(t,J=7.1Hz,2H),
2.42-2.95(br,1H),2.54(t,J=6.8Hz,2H),
10 2.61(dd,J=12.4,5.1Hz,1H),2.80(dd,J=12.4,10.1Hz,1H),
3.67(s,3H),3.79(t,J=5.7Hz,1H),3.96-4.09(m,1H),4.18-
4.34(m,1H),5.33(dd,J=15.5,8.5Hz,1H),5.48(dd,J=15.5,5.8Hz,
1H)

IR(neat) cm⁻¹ ;

15 3514,2929,2855,1740,1472,1463,1451,1388,1361,1256,1208,
1174,1100,1052,1005,973,922,900,836,776,668

6-Thia-16,17,18,19,20-pentanol-15-cyclohexyl-PGF₁β
methyl ester 11,15-bis(tert-butyldimethylsilyl ether)

¹H-NMR(CDCl₃,200MHz)δppm ;

20 -0.01(s,3H),0.02(s,3H),0.03(s,6H),0.72-2.16(m,19H),
0.86(s,9H),0.90(s,9H),2.25-2.88(m,3H),2.33(t,J=7.1Hz,2H),
2.37(dd,J=13.2,10.7Hz,1H),2.81(dd,J=13.2,3.8Hz,1H),3.67(
s,3H),3.76-3.86(m,1H),3.96-4.28(m,2H),5.33-5.54(m,2H)

IR(neat) ;

25 3459,2952,2929,2855,1740,1472,1463,1451,1361,1256,1208,
1174,1116,1067,1006,973,923,899,836,776,670

(4) Following the substantially same manner as in Example 1(4) using 6-thia-16,17,18,19,20-pentanol-15-

cyclohexyl-PGF₁α methyl ester 11,15-bis(tert-butylldimethylsilyl ether) obtained in the above (3), thereby 6-thia-9-deoxy-9β-chloro-16,17,18,19,20-pentanor-15-cyclohexyl-PGF₁α methyl ester 11,15-bis(tert-butylldimethylsilyl ether) was obtained.

¹H-NMR(CDCl₃, 200MHz) δppm ;

-0.01(s, 3H), 0.03(s, 9H), 0.78-1.86(m, 15H), 0.87(s, 9H),

0.90(s, 9H), 1.95-2.46(m, 4H), 2.33(t, J=7.3Hz, 2H),

2.53(t, J=7.0Hz, 2H), 2.66(dd, J=13.0, 5.5Hz, 1H),

2.75(dd, J=13.0, 5.4Hz, 1H), 3.67(s, 3H), 3.74-3.87(m, 1H),

4.00-4.36(m, 2H), 5.41(dd, J=15.4, 7.5Hz, 1H),

5.53(dd, J=15.4, 5.3Hz, 1H)

IR(neat) cm⁻¹ ;

2952, 2929, 2855, 1740, 1472, 1463, 1451, 1436, 1388, 1361, 1256,

1203, 1170, 1100, 1006, 973, 939, 900, 836, 776, 670

(5) Following the substantially same manner as in Example 1(5) using the compound obtained in the above (4), thereby the title compound was obtained.

¹H-NMR(CDCl₃, 200MHz) δppm ;

0.80-2.46(m, 21H), 2.34(t, J=7.0Hz, 2H), 2.54(t, J=7.0Hz, 2H),

2.64(dd, J=13.3, 5.2Hz, 1H), 2.77(dd, J=13.3, 4.7Hz, 1H), 3.68(s,

3H), 3.78-3.91(m, 1H), 4.09-4.36(m, 2H),

5.51(dd, J=15.2, 7.4Hz, 1H), 5.64(dd, J=15.2, 6.4Hz, 1H)

IR(KBr) cm⁻¹ ;

3469, 3366, 2925, 2851, 1741, 1715, 1451, 1432, 1350, 1290, 1232,

1169, 1142, 1073, 986, 970, 916, 890, 848, 741, 626, 494

Example 8

6-Thia-9-deoxy-9β-chloro-16,17,18,19,20-pentanor-15-

cyclohexyl-PGF₁α (Compound 103)

Following the substantially same manner as in Example 2 using the compound obtained in Example 7, thereby the title compound was obtained.

5 ¹H-NMR(CDCl₃, 200MHz)δppm ;

0.80-2.90(m, 23H), 2.38(t, J=6.8Hz, 2H), 3.78-3.94(m, 1H),

4.06-5.30(m, 5H), 5.51(dd, J=15.3, 7.0Hz, 1H),

5.63(dd, J=15.3, 6.3Hz, 1H)

IR(neat) cm⁻¹ ;

10 3368, 2924, 2853, 1708, 1450, 1413, 1278, 1224, 1083, 973, 892, 844,
757, 666

Example 9

6-Thia-9-deoxy-9β-chloro-16,17,18,19,20-pentanol-15-cyclohexyl-13,14-dihydro-PGF₁α methyl ester (Compound 124)

15 (1) Following the substantially same manner as in Example 7(1) using (3R)-1-iodo-3-(tert-

butyldimethylsiloxy)-3-cyclohexylpropane in place of

(1E,3S)-1-iodo-3-(tert-butyldimethylsiloxy)-3-cyclohexyl-1-propene in Example 7(1), thereby (3R,4R)-2-methylene-3-

20 [(3R)-3-(tert-butyldimethylsiloxy)-3-cyclohexyl-1-propyl]-4-(tert-butyldimethylsiloxy)cyclopentan-1-one was obtained.

¹NMR(CDCl₃, 200MHz)δppm ;

0.02(s, 3H), 0.03(s, 3H), 0.06(s, 3H), 0.08(s, 3H), 0.55-

1.85(m, 15H), 0.88(s, 9H), 0.89(s, 9H), 2.24-2.38(m, 1H), 2.53-

25 2.72(m, 1H), 2.62(dd, J=18.1, 5.9Hz, 1H), 3.37-3.49(m, 1H),

4.06-4.17(m, 1H), 5.27-5.32(m, 1H), 6.08(d, J=2.2Hz, 1H)

IR(neat) cm⁻¹ ;

2954, 2929, 2856, 1734, 1642, 1473, 1463, 1362, 1256, 1089, 1072,

1006,939,836,775,670

(2) Following the substantially same manner as in Example 1(2) using the compound obtained in the above (1) in place of (3R,4R)-2-methylene-3-[(3S)-3-(tert-butylldimethylsiloxyl)-3-cyclohexylprop-1-ynyl]-4-(tert-butylldimethylsiloxyl)cyclopentan-1-one in Example 1(2), thereby 6-thia-16,17,18,19,20-pentanor-15-cyclohexyl-13,14-dihydro-PGE₁ methyl ester 11,15-bis(tert-butylldimethylsilyl ether) was obtained.

10 ¹H-NMR(CDCl₃,200MHz)δppm ;
 0.03(s,6H),0.05(s,3H),0.08(s,3H),0.78-1.88(m,21H),
 0.88(s,9H),0.89(s,9H),2.21(dd,J=18.1,5.4Hz,1H),2.33(t,J=7.3Hz,2H),2.51(t,J=7.0Hz,2H),2.59(ddd,J=18.1,6.2,0.6Hz,1H),2.78(dd,J=12.9,7.1Hz,1H),2.87(dd,J=12.9,4.8Hz,1H),3.3
 15 2-3.50(m,1H),3.67(s,3H),4.02-4.17(m,1H)
 IR(neat) cm⁻¹ ;
 2930,2854,1746,1740,1472,1463,1451,1361,1256,1202,1158,
 1110,1072,1033,1006,940,882,836,775,668

(3) Following the substantially same manner as in Example 1(3) using the compound obtained in the above (2), thereby the compounds described below were obtained.

6-Thia-16,17,18,19,20-pentanor-15-cyclohexyl-13,14-dihydro-PGF_{1α} methyl ester 11,15-bis(tert-butylldimethylsilyl ether)

25 ¹H-NMR(CDCl₃,200MHz)δppm ;
 0.03(2s,6H),0.08(s,6H),0.72-1.93(m,23H),0.88(s,9H),
 0.89(s,9H),2.34(t,J=7.0Hz,2H),2.57(t,J=6.9Hz,2H),
 2.63(dd,J=12.5,5.1Hz,1H),2.88(dd,J=12.5,9.0Hz,1H),2.96-

3.12(br,1H),3.32-3.45(m,1H),3.67(s,3H),3.94-4.04(m,1H),
4.10-4.30(m,1H)

IR(neat) cm^{-1} ;

3514,2929,2855,1740,1472,1463,1451,1436,1387,1361,1256,
5 1202,1174,1089,1072,1029,1006,939,868,836,774,667

6-Thia-16,17,18,19,20-pentanol-15-cyclohexyl-13,14-
dihydro-PGF₁ β methyl ester 11,15-bis(tert-
butyldimethylsilyl ether)

¹H-NMR(CDCl₃,200MHz) δ ppm;

10 0.03(2s,12H),0.72-2.08(m,24H),0.87(s,9H),0.89(s,9H),
2.34(t,J=7.1Hz,2H),2.45(dd,J=12.9,10.4Hz,1H),2.57(t,J=7.
0Hz,2H),2.82(dd,J=12.9,4.4Hz,1H),3.29-3.46(m,1H),
3.68(s,3H),3.86-4.00(m,1H),4.12-4.29(m,1H)

IR(neat) cm^{-1} ;

15 3436,2929,2855,1740,1472,1463,1451,1361,1256,1208,1174,
1083,1072,1006,880,835,774,668

(4) Following the substantially same manner as in
Example 1(4) using 6-thia-16,17,18,19,20-pentanol-15-
cyclohexyl-13,14-dihydro-PGF₁ α methyl ester 11,15-bis(tert-
20 butyldimethylsilyl ether) obtained in the above (3),
thereby 6-thia-9-deoxy-9 β -chloro-16,17,18,19,20-pentanol-
15-cyclohexyl-13,14-dihydro-PGF₁ α methyl ester 11,15-
bis(tert-butyldimethylsilyl ether) was obtained.

¹H-NMR(CDCl₃,200MHz) δ ppm;

25 0.03(s,6H),0.04(s,3H),0.05(s,3H),0.70-2.82(m,23H),
0.87(s,9H),0.89(s,9H),2.34(t,J=7.1Hz,2H),2.54(t,J=7.0Hz,
2H),2.66(dd,J=13.0,6.6Hz,1H),2.75(dd,J=13.0,6.6Hz,1H),
3.33-3.46(m,1H),3.68(s,3H),3.92-4.30(m,2H)

IR(neat) cm^{-1} ;

2929,2855,1741,1472,1463,1451,1386,1361,1256,1202,1170,
1088,1072,1006,939,899,836,812,774,669

(5) Following the substantially same manner as in
5 Example 1(5) using the compound obtained in the above (4),
thereby the title compound was obtained.

$^1\text{H-NMR}(\text{CDCl}_3, 200\text{MHz})\delta\text{ppm}$;

0.80-2.90(m, 25H), 2.35(t, J=7.0Hz, 2H), 2.57(t, J=7.0Hz, 2H),
2.71(dd, J=13.1, 5.9Hz, 1H), 2.80(dd, J=13.1, 5.3Hz, 1H), 3.25-
10 3.55(m, 1H), 3.68(s, 3H), 4.00-4.38(m, 2H)

IR(neat) cm^{-1} ;

3400,2924,2853,1740,1450,1418,1348,1273,1208,1175,1088,
1063,996,892,844,503

Example 10

15 6-Thia-9-deoxy-9 β -chloro-16,17,18,19,20-pentanor-15-
cyclohexyl-13,14-dihydro-PGF $_1\alpha$ (Compound 127)

Following the substantially same manner as in Example
2 using the compound obtained in Example 9, thereby the
title compound was obtained.

20 $^1\text{H-NMR}(\text{CDCl}_3, 200\text{MHz})\delta\text{ppm}$;

0.78-2.88(m, 27H), 2.39(t, J=6.8Hz, 2H), 3.20-4.80(br, 3H),
3.35-3.53(m, 1H), 4.05-4.36(m, 2H)

IR(neat) cm^{-1} ;

3368,2924,2853,1708,1450,1418,1278,1224,1088,1063,975,
25 893,758,667

Example 11

3-Oxa-6-thia-9-deoxy-9 β -chloro-16,17,18,19,20-
pentanor-15-cyclohexyl-13,14-didehydro-PGF $_1\alpha$ methyl ester

(Compound 84)

(1) Following the substantially same manner as in Example 1(2) using methyl 5-mercapto-3-oxapentanoate in place of methyl 5-mercaptopentanoate in Example 1(2),

5 thereby 3-oxa-6-thia-16,17,18,19,20-pentano-15-cyclohexyl-13,14-didehydro-PGE₁ methyl ester 11,15-bis(tert-butyl dimethylsilyl ether) was obtained.

¹H-NMR(CDCl₃,200MHz)δppm ;

0.08(s,3H),0.09(s,3H),0.10(s,3H),0.13(s,3H),0.82-
10 1.92(m,11H),0.89(s,9H),0.90(s,9H),2.22(dd,J=18.0,6.4Hz,
1H),2.40-2.82(m,2H),2.77(t,J=6.7Hz,2H), 2.92(d,5.9Hz,2H),
3.09-3.20(m,1H),3.71(t,J=6.7Hz,2H), 3.76(s,3H),
4.08(dd,J=6.2,1.8Hz,1H),4.13(s,2H),4.28-4.42(m,1H)
IR(neat) cm⁻¹ ;
15 2930,2855,2236,1752,1472,1464,1451,1390,1362,1252,1208,
1138,1066,1006,940,898,837,779,670,579

(2) Following the substantially same manner as in Example 1(3) using the compound obtained in the above (1), thereby the compounds described below were obtained.

20 3-Oxa-6-thia-16,17,18,19,20-pentano-15-cyclohexyl-13,14-didehydro-PGF₁α methyl ester 11,15-bis(tert-butyl dimethylsilyl ether)

¹H-NMR(CDCl₃,200MHz)δppm ;

0.08(s,3H),0.09(s,3H),0.10(s,6H),0.83-2.22(m,15H),
25 0.88(s,9H),0.90(s,9H),2.50-2.64(m,1H),2.72-2.96(m,4H),
3.74(t,J=6.6Hz,2H),3.76(s,3H),4.07(dd,J=6.4,1.8Hz,1H),
4.14(s,2H),4.18-4.33(m,2H)
IR(neat) cm⁻¹

3514, 2929, 2855, 2235, 1758, 1472, 1464, 1451, 1388, 1362, 1251,
1214, 1138, 1100, 1062, 1006, 927, 898, 837, 777, 668

3-Oxa-6-thia-16,17,18,19,20-pentanol-15-cyclohexyl-
13,14-didehydro-PGF₁β methyl ester 11,15-bis(tert-

5 butyldimethylsilyl ether)

¹H-NMR(CDCl₃, 200MHz) δppm ;

0.07(s, 3H), 0.08(s, 6H), 0.11(s, 3H), 0.83-2.09(m, 15H),
0.88(s, 9H), 0.90(s, 9H), 2.35(ddd, J=10.0, 6.3, 1.8Hz, 1H),
2.46-3.12(m, 4H), 3.67-3.81(m, 2H), 3.76(s, 3H), 4.05-
10 4.30(m, 2H), 4.08(dd, J=6.3, 1.6Hz, 1H), 4.13(s, 2H)

IR(neat) cm⁻¹ ;

3469, 2952, 2929, 2855, 2236, 1758, 1472, 1463, 1451, 1389, 1361,
1252, 1214, 1138, 1066, 1006, 927, 898, 837, 777, 669

(3) Following the substantially same manner as in
15 Example 1(4) using 3-oxa-6-thia-16,17,18,19,20-pentanol-15-
cyclohexyl-13,14-didehydro-PGF₁α methyl ester 11,15-
bis(tert-butyldimethylsilyl ether) obtained in the above
(2) under an argon stream, thereby 3-oxa-6-thia-9-deoxy-9β-
chloro-16,17,18,19,20-pentanol-15-cyclohexyl-13,14-
20 didehydro-PGF₁α methyl ester 11,15-bis(tert-
butyldimethylsilyl ether) was obtained.

¹H-NMR(CDCl₃, 200MHz) δppm ;

0.07(s, 3H), 0.08(s, 3H), 0.09(s, 3H), 0.11(s, 3H), 0.82-
1.92(m, 11H), 0.88(s, 9H), 0.90(s, 9H), 2.13-2.42(m, 3H),
25 2.57(ddd, J=9.1, 5.3, 1.8Hz, 1H), 2.81(t, J=6.7Hz, 2H), 2.88(dd,
J=5.4, 0.8Hz, 2H), 3.74(t, J=6.7Hz, 2H), 3.77(s, 3H), 4.05-
4.34(m, 2H), 4.08(dd, J=6.2, 1.8Hz, 1H), 4.14(s, 2H)

IR(neat) cm⁻¹ ;

2952,2929,2855,2236,1758,1746,1472,1464,1451,1389,1362,
1252,1208,1138,1100,1006,939,898,837,777,669

(4) Following the substantially same manner as in Example 1(5) using the compound obtained in the above (3),

5 thereby the title compound was obtained.

 $^1\text{H-NMR}(\text{CDCl}_3, 200\text{MHz}) \delta \text{ppm};$

0.92-2.00 (m, 13H), 2.22-2.48 (m, 3H),

2.65 (ddd, J=10.0, 6.4, 1.9 Hz, 1H), 2.83 (t, J=6.6 Hz, 2H),

2.92 (d, J=5.1 Hz, 2H), 3.75 (t, J=6.6 Hz, 2H), 3.77 (s, 3H), 4.10-

10 4.29 (m, 2H), 4.15 (s, 2H), 4.33-4.46 (m, 1H)

IR(neat) cm^{-1} ;

3400, 2925, 2853, 2236, 1752, 1746, 1440, 1288, 1218, 1138, 1083,

1011,955,893,834,704,579

Example 12

15 3-Oxa-6-thia-9 β -chloro-13,14-didehydro-

16,17,18,19,20-pentano-15-cyclohexyl-9-deoxy-PGF₁α

(Compound 97)

Following the substantially same manner as in Example 2 using the compound obtained in Example 11, thereby the

20 title compound was obtained.

$$^1\text{H-NMR}(\text{CDCl}_3, 200\text{MHz}) \delta \text{ppm};$$

0.92-1.94 (m, 11H), 2.16-2.48 (m, 3H),

2.64 (ddd, $J=10.1, 6.8, 1.8\text{ Hz}$, 1H), 2.72-3.07 (m, 2H),

2.83 (t, J=6.4Hz, 2H), 3.77 (t, J=6.4Hz, 2H), 3.92-4.64 (m, 6H),

25 4.17(s, 2H)

IR(neat) cm^{-1} ;

3368, 2924, 2854, 2236, 1734, 1450, 1429, 1348, 1278, 1230, 1132,

1083,1008,954,893,834,758,676,578

Example 13

3,6-Dithia-9-deoxy-9 β -chloro-16,17,18,19,20-pentano-
15-cyclohexyl-13,14-didehydro-PGF₁ α methyl ester (Compound
77)

5 (1) Following the substantially same manner as in
Example 1(2) using methyl 5-mercapto-3-thiapentanoate in
place of methyl 5-mercaptopentanoate in Example 1(2),
thereby 3,6-dithia-16,17,18,19,20-pentano-15-cyclohexyl-
13,14-didehydro-PGE₁ methyl ester 11,15-bis(tert-
10 butyldimethylsilyl ether) was obtained.

¹H-NMR(CDCl₃,200MHz) δ ppm ;

0.08(s,3H),0.09(s,3H),0.10(s,3H),0.13(s,3H),0.84-
1.93(m,11H),0.89(s,9H),0.90(s,9H),
2.22(dd,J=18.0,6.4Hz,1H),2.41-2.55(m,1H),2.64-
15 2.96(m,7H),3.07-3.18(m,1H),3.27(s,2H),3.75(s,3H),
4.09(dd,J=6.4,1.5Hz,1H),4.29-4.41(m,1H)

IR(neat) cm⁻¹ ;

2929,2855,2236,1746,1472,1464,1436,1407,1390,1362,1257,
1121,1065,1006,940,898,837,778,670

20 (2) Following the substantially same manner as in
Example 1(3) using the compound obtained in the above (1),
thereby the compounds described below were obtained.

3,6-Dithia-16,17,18,19,20-pentano-15-cyclohexyl-
13,14-didehydro-PGF₁ α methyl ester 11,15-bis(tert-
25 butyldimethylsilyl ether)

¹H-NMR(CDCl₃,200MHz) δ ppm ;

0.08(s,3H),0.09(s,3H),0.10(s,6H),0.84-2.20(m,15H),
0.89(s,9H),0.90(s,9H),2.50-2.64(m,1H),2.73-2.96(m,6H),

3.27(s, 2H), 3.75(s, 3H), 4.08(dd, J=6.2, 1.8Hz, 1H), 4.20-
4.33(m, 2H)

IR(neat) cm^{-1} ;

3436, 2929, 2855, 2236, 1740, 1472, 1463, 1436, 1387, 1362, 1256,
5 1100, 1062, 1006, 898, 836, 777, 670

3,6-Dithia-16,17,18,19,20-pentanol-15-cyclohexyl-
13,14-didehydro-PGF₁ β methyl ester 11,15-bis(tert-
butyldimethylsilyl ether)

¹H-NMR(CDCl₃, 200MHz) δ ppm;

10 0.07(s, 3H), 0.08(s, 6H), 0.11(s, 3H), 0.83-2.07(m, 15H),
0.88(s, 9H), 0.90(s, 9H), 2.36(ddd, J=10.0, 6.4, 1.5Hz, 1H),
2.49-3.06(m, 4H), 2.56(dd, J=13.2, 9.4Hz, 1H),
3.00(dd, J=13.2, 4.3Hz, 1H), 3.27(s, 2H), 3.75(s, 3H), 4.04-
4.31(m, 3H)

15 IR(neat) cm^{-1} ;

3468, 2929, 2855, 2236, 1740, 1472, 1464, 1436, 1388, 1362, 1338,
1279, 1252, 1100, 1066, 1006, 898, 836, 777, 670

(3) Following the substantially same manner as in
Example 1(4) using 3,6-dithia-16,17,18,19,20-pentanol-15-
20 cyclohexyl-13,14-didehydro-PGF₁ α methyl ester 11,15-
bis(tert-butyldimethylsilyl ether) obtained in the above
(2), thereby 3,6-dithia-9-deoxy-9 β -chloro-16,17,18,19,20-
pentanol-15-cyclohexyl-13,14-didehydro-PGF₁ α methyl ester
11,15-bis(tert-butyldimethylsilyl ether) was obtained.

25 ¹H-NMR(CDCl₃, 200MHz) δ ppm;

0.08(s, 6H), 0.09(s, 3H), 0.11(s, 3H), 0.80-1.92(m, 11H),
0.88(s, 9H), 0.90(s, 9H), 2.14-2.39(m, 3H),
2.57(ddd, J=9.1, 5.0, 1.6Hz, 1H), 2.74-2.96(m, 6H),

3.27(s, 2H), 3.75(t, J=6.7Hz, 2H), 4.05-4.34(m, 2H),

4.09(dd, J=6.3, 1.6Hz, 1H)

IR(neat) cm^{-1} ;

2929, 2855, 2236, 1740, 1472, 1464, 1436, 1389, 1362, 1278, 1257,

5 1100, 1006, 962, 927, 898, 836, 778, 669, 588

(5) Following the substantially same manner as in Example 1(5) using the compound obtained in the above (4), thereby the title compound was obtained.

^1H -NMR(CDCl_3 , 200MHz) δ ppm;

10 0.98-2.02(m, 13H), 2.22-2.47(m, 3H),

2.62(ddd, J=10.1, 6.4, 1.8Hz, 1H), 2.75-2.99(m, 6H),

3.28(s, 2H), 3.76(s, 3H), 4.10(m, 2H), 4.06-4.27(m, 2H), 4.32-

4.47(m, 1H)

IR(neat) cm^{-1} ;

15 3400, 2925, 2852, 2236, 1734, 1730, 1436, 1284, 1203, 1142, 1083,

1008, 893, 833, 773, 692, 578

Example 14

3,6-Dithia-9-deoxy-9 α -chloro-16,17,18,19,20-pentanol-15-cyclohexyl-13,14-didehydro-PGF $_1\beta$ methyl ester (Compound
20 193)

(1) Following the substantially same manner as in Example 1(4) using 3,6-dithia-16,17,18,19,20-pentanol-15-cyclohexyl-13,14-didehydro-PGF $_1\beta$ methyl ester 11,15-bis(tert-butyldimethylsilyl ether) obtained in Example
25 13(2), thereby 3,6-dithia-9-deoxy-9 α -chloro-16,17,18,19,20-pentanol-15-cyclohexyl-13,14-didehydro-PGF $_1\beta$ methyl ester 11,15-bis(tert-butyldimethylsilyl ether) was obtained, followed by carrying out the substantially same manner as

in Example 1(5) to give the title compound.

$^1\text{H-NMR}(\text{CDCl}_3, 200\text{MHz})\delta\text{ppm};$

0.87-2.34(m, 15H), 2.57-3.00(m, 8H), 3.28(s, 2H), 3.75(s, 3H),
4.12-4.40(m, 2H), 4.53-4.63(m, 1H)

5 IR(neat) $\text{cm}^{-1};$

3400, 2924, 2851, 2236, 1734, 1436, 1283, 1141, 1082, 1009, 893,
837, 689

Example 15

3,6-Dithia-9-deoxy-9 β -chloro-16,17,18,19,20-pentanor-
10 15-cyclohexyl-13,14-didehydro-PGF $_1\alpha$ (Compound 89)

Following the substantially same manner as in Example
2 using the compound obtained in Example 13, thereby the
title compound was obtained.

$^1\text{H-NMR}(\text{CDCl}_3, 200\text{MHz})\delta\text{ppm};$

15 0.92-2.00(m, 11H), 2.15-3.12(m, 10H), 3.23(d, J=14.2Hz, 1H),
3.32(d, J=14.2Hz, 1H), 3.57-4.03(br, 3H), 4.06-4.28(m, 1H),
4.24(dd, J=6.2, 2.0Hz, 1H), 4.34-4.49(m, 1H)

IR(neat) $\text{cm}^{-1};$

3368, 2925, 2853, 2236, 1718, 1450, 1424, 1278, 1206, 1149, 1082,
20 1005, 957, 921, 893, 876, 833, 758, 670, 578

Experiment [Measurement of cAMP production promoting
action in EBTr [NBL-4] cell derived from bovine embryonic
trachea]

According to the method of Ito et al. in *Br. J.*
25 *Pharmacol.*, vol. 99, page 13-14 (1990), the following test
was carried out.

That is, EBTr [NBL-4] cells derived from bovine
embryonic trachea (produced by Dainippon Pharmaceutical

Co.) were inoculated on 24-well plates (6×10^4 cells/well) (manufactured by Sumitomo Bakelite Co.), and cultured on a growth medium (MEM Earle's medium including 10% calf serum, 2mM glutamine and non-essential amino acids) for 48 hours, followed by cultivation on 0.5 ml of a growth medium including the test compound and 0.5 mM 3-isobutyl-1-methylxanthine) for 15 minutes. After the completion of the reaction, the cells were washed with a phosphate buffer (not including Ca^{++} and Mg^{++}), 0.6 ml of 65% aqueous ethanol solution was added, followed by allowing to stand at 4°C for an hour, and the resulting cAMP was extracted. After evaporation of the solvent by a centrifugal evaporator, the amount of cAMP was measured by using a cAMP EIA System (manufactured by Amersham Co.).

When an amount of cAMP obtained by adding PGD_2 in a concentration of $10 \mu\text{M}$ was regarded as 100%, a concentration required to produce 50% of the amount of cAMP was measured as EC_{50} .

Results are shown in Table 1.

20

Table 1

Compound	cAMP production promoting action $\text{EC}_{50}(\text{nM})$
Compound 19	17.3
Compound 97	5.13
PGD_2	124

(note) Compounds 19 and 97 are those prepared in the examples as described above. The test compounds were each used as a form of an ethanol solution, and compared with a

vehicle-treated group as a control.

It is found from the above results that Compounds 19 and 97 have a strong cAMP production promoting action.


INDUSTRIAL APPLICABILITY

5 The compounds of the present invention have a PGD₂-like agonistic action, therefore they are useful as therapeutic agents of circulatory diseases such as renal diseases, ischemic heart diseases, heart failure or hypertension, and glaucoma.

10 In addition, the compounds of the present invention have not only a sufficient sleep-inducing action, but also excellent stability and intracerebral transition, therefore they are useful as a drug having a sleep-inducing action.

CLAIMS

1. A prostaglandin derivative represented by Formula (I):



wherein X is a halogen atom in the α - or β -position, Y is an ethylene group, a vinylene group or an ethynylene group,

A is a group represented by the formula: $O(CH_2)_n$,

$S(O)_p(CH_2)_n$,

$O(CH_2)_qO(CH_2)_r$,

$O(CH_2)_qS(O)_p(CH_2)_r$,

$S(O)_p(CH_2)_qS(O)_p(CH_2)_r$ or

$S(O)_p(CH_2)_qO(CH_2)_r$

(wherein n is an integer of 1 to 5, p is 0, 1 or 2, q is an integer of 1 to 3, and r is 0 or 1),

R^1 is a C_{3-10} cycloalkyl group, a C_{1-4} alkyl- C_{3-10}

cycloalkyl group, a C_{3-10} cycloalkyl- C_{1-4} alkyl group, a

C_{5-10} alkyl group, a C_{5-10} alkenyl group, a C_{5-10} alkynyl group or a bridged cyclic hydrocarbon group,

R^2 is a hydrogen atom, a C_{1-10} alkyl group or a C_{3-10} cycloalkyl group, and

m is 0, 1 or 2], a pharmaceutically acceptable salt thereof or a hydrate thereof.

2. The prostaglandin derivative of Formula (I) according




to Claim 1 wherein R¹ is a C₃₋₁₀ cycloalkyl group, a C₁₋₄ alkyl-C₃₋₁₀ cycloalkyl group, a C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl group, a branched C₅₋₁₀ alkyl group, a branched C₅₋₁₀ alkenyl group, a branched C₅₋₁₀ alkynyl group or a bridged cyclic hydrocarbon group; the pharmaceutically acceptable salt thereof or the hydrate thereof.

3. The prostaglandin derivative of Formula (I) according to Claim 2 wherein X is a chlorine or bromine atom in the α - or β -position, R¹ is a C₃₋₁₀ cycloalkyl group, a C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl group or a branched C₅₋₁₀ alkenyl group, and R² is a hydrogen atom or a C₁₋₁₀ alkyl group; the pharmaceutically acceptable salt thereof or the hydrate thereof.

4. The prostaglandin derivative of Formula (I) according to any one of Claims 1 to 3 wherein Y is a vinylene group; the pharmaceutically acceptable salt thereof or the hydrate thereof.

5. The prostaglandin derivative of Formula (I) according to any one of Claims 1 to 3 wherein Y is an ethynylene group; the pharmaceutically acceptable salt thereof or the hydrate thereof.

6. The prostaglandin derivative of Formula (I) according to any one of Claims 1 to 5 wherein is A is a group represented by the formula:



(wherein n is an integer of 1 to 5, p is 0, 1 or 2, q is an


integer of 1 to 3, and r is 0 or 1); the pharmaceutically acceptable salt thereof or the hydrate thereof.

7. The prostaglandin derivative of Formula (I) according to Claim 6 wherein p is 0; the pharmaceutically acceptable salt thereof or the hydrate thereof.

8. A pharmaceutical preparation which comprises as an effective ingredient the prostaglandin derivative according to any one of Claims 1 to 7, the pharmaceutically acceptable salt thereof or the hydrate thereof.

ABSTRACT

A prostaglandin derivative represented by the formula:



wherein X is a halogen atom in the α - or β -position, Y is
 5 an ethylene group, a vinylene group or an ethynylene group,
 A is a group represented by the formula: $O(CH_2)_n$,
 $S(O)_p(CH_2)_n$,
 $O(CH_2)_qO(CH_2)_r$,
 $O(CH_2)_qS(O)_p(CH_2)_r$,
 10 $S(O)_p(CH_2)_qS(O)_p(CH_2)_r$ or
 $S(O)_p(CH_2)_qO(CH_2)_r$
 (wherein n is an integer of 1 to 5, p is 0, 1 or 2, q is an
 integer of 1 to 3, and r is 0 or 1),
 R^1 is a C_{3-10} cycloalkyl group, a C_{1-4} alkyl- C_{3-10}
 15 cycloalkyl group, a C_{3-10} cycloalkyl- C_{1-4} alkyl group, a
 C_{5-10} alkyl group, a C_{5-10} alkenyl group, a C_{5-10} alkynyl
 group or a bridged cyclic hydrocarbon group,
 R^2 is a hydrogen atom, a C_{1-10} alkyl group or a C_{3-10}
 cycloalkyl group, and
 20 m is 0, 1 or 2], a pharmaceutically acceptable salt thereof
 or a hydrate thereof.

The present invention is to provide novel PG

DECLARATION AND POWER OF ATTORNEY FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)

As a below named inventor, I hereby declare that: My residence, mailing address, and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

PROSTAGLANDIN DERIVATIVES

the application of which

☐ is attached hereto

OR

☒ was filed on September 8, 2000 as United States Application Number or PCT International Application Number PCT/JP00/06162 (Confirmation No. _____), and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part application(s), material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application(s) which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application(s) having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date	Priority Claimed	
			Yes	No
<u>256727/1999</u>	<u>Japan</u>	<u>Sep. 10, 1999</u>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
<u>323804/1999</u>	<u>Japan</u>	<u>Nov. 15, 1999</u>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
<u>189121/2000</u>	<u>Japan</u>	<u>Jun. 23, 2000</u>	<input checked="" type="checkbox"/>	<input type="checkbox"/>

I hereby claim domestic priority benefits under 35 United States Code §120 of any United States application(s), §119(e) of any United States provisional application(s), or §365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in a listed prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge my duty to disclose any information material to the patentability of this application as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Prior U.S. or International Application Number(s)

U.S. or International Filing Date

Status

I hereby appoint all attorneys of **SUGHRUE MION, PLLC** who are listed under the USPTO Customer Number shown below as my attorneys to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, recognizing that the specific attorneys listed under that Customer Number may be changed from time to time at the sole discretion of Sughrue Mion, PLLC, and request that all correspondence about the application be addressed to the address filed under the same USPTO Customer Number.



23373

PATENT TRADEMARK OFFICE

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

NAME OF SOLE OR FIRST INVENTOR:			
Given Name (first and middle [if any]) <u>Fumie</u>		Family Name or Surname <u>SATO</u>	
Inventor's Signature <u>Fumie Sato</u>		Date <u>February 26, 2002</u>	
Residence: City <u>Kanagawa</u>	State <u>JPX</u>	Country <u>Japan</u>	Citizenship <u>Japanese</u>
Mailing Address: <u>2-1-901, Kugenmahigasi, Fujisawa-shi, Kanagawa 251-0026 Japan</u>			
City <u>Kanagawa</u>	State	Zip <u>251-0026</u>	Country <u>Japan</u>
NAME OF SECOND INVENTOR:			
Given Name (first and middle [if any]) <u>Tohru</u>		Family Name or Surname <u>TANAMI</u>	
Inventor's Signature <u>Tohru Tanami</u>		Date <u>February 26, 2002</u>	
Residence: City <u>Tokyo</u>	State <u>JPX</u>	Country <u>Japan</u>	Citizenship <u>Japanese</u>
c/o TAISHO PHARMACEUTICAL CO., LTD. of 24-1, Takata 3-chome, Toshima-ku,			
Mailing Address: <u>Tokyo 170-8633 Japan</u>			
City <u>Tokyo</u>	State	Zip <u>170-8633</u>	Country <u>Japan</u>
NAME OF THIRD INVENTOR:			
Given Name (first and middle [if any]) <u>Hideo</u>		Family Name or Surname <u>TANAKA</u>	
Inventor's Signature <u>Hideo Tanaka</u>		Date <u>February 26, 2002</u>	
Residence: City <u>Tokyo</u>	State <u>JPX</u>	Country <u>Japan</u>	Citizenship <u>Japanese</u>
c/o TAISHO PHARMACEUTICAL CO., LTD. of 24-1, Takata 3-chome, Toshima-ku,			
Mailing Address: <u>Tokyo 170-8633 Japan</u>			
City <u>Tokyo</u>	State	Zip <u>170-8633</u>	Country <u>Japan</u>
NAME OF FOURTH INVENTOR:			
Given Name (first and middle [if any]) <u>Naoya</u>		Family Name or Surname <u>ONO</u>	
Inventor's Signature <u>Naoya Ono</u>		Date <u>February 26, 2002</u>	
Residence: City <u>Tokyo</u>	State <u>JPX</u>	Country <u>Japan</u>	Citizenship <u>Japanese</u>
c/o TAISHO PHARMACEUTICAL CO., LTD. of 24-1, Takata 3-chome, Toshima-ku,			
Mailing Address: <u>Tokyo 170-8633 Japan</u>			
City <u>Tokyo</u>	State	Zip <u>170-8633</u>	Country <u>Japan</u>
NAME OF FIFTH INVENTOR:			
Given Name (first and middle [if any]) <u>Makoto</u>		Family Name or Surname <u>YAGI</u>	
Inventor's Signature <u>Makoto Yagi</u>		Date <u>February 26, 2002</u>	
Residence: City <u>Tokyo</u>	State <u>JPX</u>	Country <u>Japan</u>	Citizenship <u>Japanese</u>
c/o TAISHO PHARMACEUTICAL CO., LTD. of 24-1, Takata 3-chome, Toshima-ku,			
Mailing Address: <u>Tokyo 170-8633 Japan</u>			
City <u>Tokyo</u>	State	Zip <u>170-8633</u>	Country <u>Japan</u>

NAME OF SIXTH INVENTOR:			
Given Name (first and middle [if any])		Family Name or Surname	
Hitomi		HIRANO	
Inventor's Signature			Date
Hitomi Hirano			February 26, 2002
Residence: City	State	Country	Citizenship
Tokyo	JPN	Japan	Japanese
Mailing Address: c/o TAISHO PHARMACEUTICAL CO., LTD. of 24-1, Takata 3-chome, Toshima-ku, Tokyo 170-8633 Japan			
City	State	Zip	Country
Tokyo		170-8633	Japan
NAME OF SEVENTH INVENTOR:			
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature			Date
Residence: City	State	Country	Citizenship
Mailing Address:			
City	State	Zip	Country
NAME OF EIGHTH INVENTOR:			
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature			Date
Residence: City	State	Country	Citizenship
Mailing Address:			
City	State	Zip	Country
NAME OF NINTH INVENTOR:			
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature			Date
Residence: City	State	Country	Citizenship
Mailing Address:			
City	State	Zip	Country
NAME OF TENTH INVENTOR:			
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature			Date
Residence: City	State	Country	Citizenship
Mailing Address:			
City	State	Zip	Country